corporate responsibility report feel well live longergsk corporate responsibility report gsk gsk mission improve cover image donate antiparasitic treatment quality human life enable people million schoolage child develop world help combat effect feel well live long intestinal worm cycle poverty contribute intestinal worm report describe progress neglect tropical disease target research funding make operating partnership dedicated operating unit establish year business responsibly use report interactive pdf allow find information guide navigation button printfriendly pdf link navigate report easily print icon navigation allow dynamic link text indicate relevant link additional useful main content print document icon text show section information include policy position separate printfriendly pdf colour clicking website gskcom search pdf information document screen mode web address relate online site interested get summary print pdf set view screen open new window responsible business performance suggest mode turn eg zoom read overview begin navigation tab print press esc toolbar section find summary page precede reveal return screen mode click tab press ctrll leave start section overview section summary return visitedgsk corporate responsibility report inside report approach health behaviour people planet governance approach health behaviour people planet manage raenspdo nesnibgialigtieesment learn find learn find help read find develop innovative embed value people thrive manage corporate responsibility read qa product improve behave ethically create inspire environmental impact governance chairman access healthcare responsibly supportive work engage chief executive patient world work environment carbonneutral value chain stakeholder overview overview overview overview governance create value improve healthcare ethical standard principle talent development carbon stakeholder engagement qa chairman global challenge sale marketing inclusion diversity water waste report chief executive officer innovative science work engage employee manage impact progress create value healthcare professional health safety wellbeing engagement commitment move forward access healthcare research practice reward recognition datum summary disease develop world manufacture supply chain summary health wellbee public policy assurance statement community patient advocacy hivaid approach tax approach section health section g behaviour section people section planet section governance engagement section gsk corporate responsibility report gsk sciencele global healthcare company make primary area business range product help pharmaceutical vaccine consumer healthcare people feel well pharmaceutical vaccine consumer healthcare live long bn develop medicine bn research vaccine bn innovative consumer value transparency treat range condition child adult product category respect people integrity turnover include respiratory disease turnover protect infectious turnover total wellness oral care cancer heart disease epilepsy disease include influenza nutrition skin health patient focus bacterial viral infection rotavirus cervical cancer measle portfolio include wellknown hiv lupus skin condition mump rubella hepatitis polio brand sensodyne commercial success like psoriasis tetanus meningitis panadol horlick group group group depends grow diverse business create innovative new product people value make widely accessible operating efficiently able grow business operate country turnover region employee region network manufacturing provide benefit patient site large rd centre uk consumer employees usa spain belgium china shareholders society usa usa europe europe emap emap japan japan gsk corporate responsibility report create value deliver innovation context heart disease respiratory illnesse sustainability business performance year potential critically important deliver continue expand access opportunity challenge bring new medicine patient innovation access product product operating environment scientific produce profitable performance ensure access create value society research continuously uncover new remain competitive fund invest understanding disease process manufacture distribute people asset key element shareholder technology billion pack product environment appropriately reward world population country world innovation patentprotected continue grow pressure extensive global presence strive brand product healthcare cost notable intensification product widely accessible developed market follow recent possible macroeconomic downturn achieve objective utilise western market develop new asset execute strategic priority innovation reimbursement approach medicine operating business responsibly agree riskshare arrangement core business model use payer past year knowledge development intellectual significant progress delivery property create value research adopt flexible pricing strategic priority manufacturing make available product approach reflect country wealth improve people health wellbeing ability pay result significant develop balanced business increase demand product geographic diversity new platform healthy society enable people live emerge economy growth particular advancement life fullest allow latestage pipeline change community prosper sustained flow increase access product world rd model time innovative product enable business leastdevelope country hold simplified business reduce cost grow profit deliver improved return price patent medicine region ensure retain longterm competitiveness shareholder develop world price reinvest fifth profit commitment responsible value aim develop new product offer sale territory base business underlie significant improvement exist local healthcare infrastructure project value apply group treatment option provide value focus integrate sustainable patient pay culture decisionmake work government insurer party develop new medicine take year value operate transparency invest billion core substantial investment able bring demonstrate respect people act research development new medicine scale significant resource expertise integrity patientfocuse ask vaccine consumer product require successful medicine require employee embody value currently evaluate investigational significant investment year period medicine diseases cancer diabetesgsk corporate responsibility report create value continue create value wide contribution primary contribution develop new product improve people health create value global company asset shareholder return make direct indirect economic social contribution country intellectual property people operate infrastructure global diverse employee base consist close employee deliver innnovative contract good service significant strategic priority benefit patient scale year gsk spend billion product expand supplier country grow deliver simplify consumer society access company contribute country operate tax system charge taxation profit value amount billion direct contribution support health wellbee local transparency respect community relevant gsk integrity patient focus reinvestment global community programme million year finally believe create value act catalyst partner organisation value new different perspective group bring think open work research charity academia company progress highlight nongovernmental organisation bn st return shareholder access medicine index number new product dividend buyback approval usa past year europe past yearsgsk corporate responsibility report qa chairman chief executive officer despite challenge q operate responsibly tie set new system allow q issue address researcher request access anonymised environment gsk commercial success patientlevel datum people participate deliver resilient aw commercial success inextricably research trial hope help aw implementation performance enhance link operate trustworthy bring advance healthcare plan commitment transparency responsible way strategy generate recognise commitment reflect clinical trial datum continue return shareholder diversify sale growth develop innovative desire ensure contribution lead commitment pricing look substantive product accessible health gain building harness manufacturing technology people benefit possible pharmaceutical company sign improve carbon footprint move increase access way align alltrial campaign clinical trial transparency value transparency respect transparency commit q board assess gsk integrity put patient clinical study report publicly available responsible performance consumer need hope initiative help bring positive return shareholder scientific understanding inform medical cg corporate responsibility committee benefit patient wide society judgement ultimately improve patient care crc chair meet time year real share value receive report progress see milestone area outline report health journey malaria vaccine publish q progress company behaviour people planet late stage clinical trial result show board continue constructively challenge make deliver longterm value rtss vaccine candidate help protect advise executive team think african infant malaria aw rd significant progress decision seek deliver company new product regulatory cg delight gsk recognise strategic priority responsible way review year gsk access medicine index potential launch new product sustain spot previous year q gsk set longerterm globally good platform growth independent credible assessment commitment year patient benefit continue work improve access medicine develop portfolio expand vaccine let know right track aw new commitment signal gsk long footprint emerge market term strategic intent play july group successfully resolve create share value span entire sir christopher gent series longstande legal matter chairman q gsk strong government primarily relate business fully align strategy build establish track record responsible performance historical sale marketing practice board recognise matter cg important outside aw commitment increase reflect company gsk today company understand priority transparency clinical trial datum demonstrate company continue action hold account effectively new value heart company level improve procedure compliance commitment help addition share information sir andrew witty marketing selling embed value communicate deliver design result clinical trial chief executive officer base culture gskgsk corporate responsibility report progress report responsible share value progress business performance health behaviour people planet year commitment transparency top access medicine commit provide access maintain rate despite reduce carbon index time st anonymise trial datum employee say proud energy use total approach publish clinical trial work gsk carbon footprint exclude authorise medicine raw material increase progress make driven high inhaler sale operate business year potential bring new responsibly report medicine vaccine patient addition disclosing enable employee volunteer result research publicly work country area accessible clinical study register pulse assignment reduce water consumption website receive average operation compare visitor month deliver vaccine world large mass vaccination programme pneumococcal disease increase proportion woman gavile introduction management pneumococcal vaccine pakistan cut total waste expect protect million revise code conduct compare child year external recognition receive external recognition responsible business approach vigeo world carbon disclosure dow jones european uk index ftsegood index access medicine index project leadership index sustainability index rank second world rank time consecutive year disappoint environmental social ftsegood index ftse carbon disclosure include dow governance new ranking leadership index jones sustainability index high scoring healthcare year review company ftse performance criterion inclusion igsk corporate responsibility report commitment health innovate address currently unmet health need improve access product irrespective people live ability pay move forward control eliminate disease affect world vulnerable people adapt open innovation rd model currently disease continue work partner support strengthen healthcare develop world apply area great unmet infrastructure anticipate improve access healthcare medical need scientific challenge include infectious disease million underserved people vs alzheimer disease viiv healthcare continue increase access medicine develop invest development vaccine not require continuous care adult child live hiv world help forwardlooke commitment refrigeration make distribution easy expensive unaid achieve goal reach million people globally antiretroviral treatment reflect global health continue build core range product format well meet need people globe include able access build year commitment contribute fight malaria need align afford product continue rd investment partnership ground strategic priority embed flexible pricing strategy innovative business help eliminate control neglect tropical disease affect value model prescription medicine vaccine increase usage billion people include elimination lymphatic filariasis able access afford product continue investment rd ongoing product donation contribution london declaration neglect tropical disease continue invest innovative crosssector partnership commitment develop reduce child mortality continue support objective eradicating polio follow significant engagement provide vaccine unicef achieve business consult broad range external stakeholder global public behaviour put interest patient people enable people thrive health expert nongovernmental organisation consumer drive value develop individual deliver socially responsible investor back robust mission commitment guide work policy strong compliance process area come year enable build previous achievement measure c ontinue drive valuesbase approach sale marketing practice c ontinue promote inclusion diversity globally gsk communicate progress effectively world interest consumer patient core continue create work environment inspire people grow begin report progress continue ensure interest safety patient consumer perform healthy resilient way new commitment report paramount importance way design undertake extend volunteering opportunity bring positive change clinical trial product quality assurance monitoring community global health provide individual development report adverse event ongoing product usage rigorously challenge need animal study work minimise planet grow business reduce impact animal welfare invest development alternative environmental impact study share animalbase datum value chain address un guiding principle human right business operation supplier relationship reduce overall carbon footprint vs transparent possible clinical trial datum include publish carbonneutral value chain clinical study report patientlevel datum outcome trial reduce water impact value chain vs medicine conduct gsk appropriate process make available researcher access anonymised patientlevel datum reduce operational waste vs scientific enquiry build sustainable supply line nutrition portfolio work demonstrate gsk interaction patient advocacy group local farmer improve agricultural practice improve yield commitment subject significant political stakeholder conduct appropriately ethically transparently competitiveness livelihood legal intellectual property restraintsgsk corporate responsibility report health section overview improve healthcare global challenge innovative science create value access healthcare focus disease develop world health wellbeing community give child well start hivaids life deworme read gsk corporate responsibility report health focus gsk play lead role global want product coalition pharmaceutical company give nongovernment organisation government accessible affordable people global health organisation commit child work control eliminate s neglect tropical need generate well start disease commitment gsk donate return need invest rd life million treatment anti parasitic treatment albendazole year deworme grow business help eliminate lymphatic filariasis lf million treatment fight intestinal worm school age child donate billion albendazole need new exist treatment increase world dose fight devastating disease population grow age million people develop intestinal worm affect billion country little access basic healthcare rise cost people worldwide big cause ill health schoolage child significant concern continue evolve business estimate million child risk model address global challenge ensure business effect include stomach pain sickness sustainable malnutrition painful debilitate intestinal worm cause stunting gsk contribute improve health develop innovative control worm physical growth affect longterm value product support disease prevention rd focus child invest brain development infect child meet unmet medical need help control eliminate future struggle attend stay alert school hindering education prospect disease affect world vulnerable people provide albendazole treatment invest expand portfolio new way partner million school age child deworme help break cycle tackle issue outside core business lack develop world healthy child healthcare infrastructure likely attend school well education give well aspire catalyst change company chance get good job change business create new headmistress local school ghana saysby control worm child model open innovation flexible pricing invest future contribute wide change industrygsk corporate responsibility report overview glance innovative science create value access healthcare disease develop world commit meeting global polio eradication initiative polio invest billion global research deliver vaccine world large initiate join london vaccine requirement procure development investigational mass vaccination programme declaration control eliminate unicef continue support medicine development include pneumococcal disease gavile neglect tropical disease initiative country world target cancer diabetes heart disease introduction synflorix pakistan declare polio free expect protect million child year bn donate billionth albendazole tablet fight lymphatic filariasis intestinal worm pledge donate health wellbeing public domain compound billion tablet year community show promise starting point new tb medicine follow screening develop country market donate million promote entire pharmaceutical library access unit establish health wellbee million compound volume medicine supply community product develop country increase nearly financial donation million unit million commit million tre canto open lab foundation double hivaid fund independent research disease viiv healthcare submit regulatory develop world gsk open lab application investigational integrase inhibitor dolutegravir spearhead firstofitskind establish programme train publish latestage clinical trial publicprivate partnership produce community health worker result show rtss vaccine new combination hiv medicine develop country meet candidate help protect african paediatric use resourcelimite setting commitment reinvest profit infant malaria country develop health infrastructure gsk corporate responsibility report overview commitment post development agenda external perspective adapt open innovation rd model viiv healthcare continue currently disease develop increase access medicine care world apply area great adult child live hiv current millennium development please company unmet medical need scientific challenge world help goal expire examine access medicine include infectious disease alzheimer unaid achieve goal reach disease million people globally antiretroviral include target health gsk index continue progress active partner ensure continue treatment improve access medicine people invest development vaccine focus health new framework develop country glaxosmithkline not require continuous refrigeration build year commitment develop post play important leadership role make distribution easy expensive contribute fight malaria continue rd investment information gsk set pace follow continue build core range product partnership ground position read reflect index format well meet need company retain place people globe include help eliminate control neglect ranking index company able access afford product tropical disease affect billion follow people include elimination embe flexible pricing strategy lymphatic filariasis closing gap gsk look forward innovative business model continue investment rd ongoe coming year observe prescription medicine vaccine product donation contribution gsk step pace increase usage able london declaration neglect progress order maintain access afford product tropical disease leadership position continue invest innovative crosssector continue support objective partnership reduce child mortality eradicate polio provide vaccine unicef achieve continue work partner support strengthen healthcare infrastructure anticipate improve access healthcare million underserved people vs wim leereveld founder ceo access medicine foundation httpwwwaccesstomedicineindexorggsk corporate responsibility report improve healthcare global challenge poverty key issue barrier role significant progress complex barrier treatment not exist gsk respond modern medicine transform challenge despite advance effective treatment million live illness world health organization recommend need disease tuberculosis fatal country need invest capita hepatitis c develop new treatment takes control treat year cost million pound year guarantee access essential health service low commercial return disease country meet target primarily affect develop country global child mortality affordability driving rate decline price lack resource prevent innovative government people buy medicine science need price reduction help create value billion people live day develop world develop world cheap medicine affordable challenge healthcare infrastructure age population lack infrastructure huge problem remain year chronic disease lack eductation develop country lack adequate healthcare facility staff number africa increase million people affect suffer global burden curable preventable illness access disease health worker medicine gdp spend luxembourg gdp spend eritrea resistance exist treatment healthcare high capita healthcare low improve america annum spend africa capita resistance antimicrobial global challenge annum spend problem disease affect affordability develop country include malaria europe people africa people noncommunicable disease child die child die age physicians physicians age population rise obesity investing age death avoid mean condition like heart disease cancer treatment diabete rise country well nutrition disease require treatment year death nurse midwive nurse midwive noncommunicable disease account prevent nearly twothird global death develop exist expect increase vaccine world people live stigma discrimination hiv discrimination stigma prevent patient million receive suffering disease hiv antiretroviral therapy asthma access treatment figure base world health statistic mortality rate live birth world bank hunger vital statistic resource density physicians total number population stated global report unaid report global aid epidemic speaker global issue un late available year global health observatorygsk corporate responsibility report innovative science create value big contribution develop global portfolio meet key innovation case study health need people world improve focus product provide investigational health scientific great value patient healthcare payer medicine development include join force innovation research provider target cancer diabetes heart disease battle candidate vaccine development new treatment substantial investment pipeline expect deliver phase iii data antimicrobial resistance vaccine consumer research development rd asset end collaboration public private partner potential launch new product gsk pharmaceutical healthcare product strong commitment open innovation year biotechnology company involve gsk advocate public policy support pioneer publicprivate collaboration scientific innovation broadly product launch include potiga tackle rise infection partialonset seizure people epilepsy mrsa resistant antibiotic meeting health need world poor votrient softtissue sarcoma rare people key research objective aggressive form cancer usa million million commit find new avamys allergic rhinitis china newdrugsbadbugs programme launch well medicine vaccine patient receive approval europe support innovative medicine initiative aim stimulate develop country poor population nimenrix vaccine invasive research discover new antibiotic middleincome country meningococcal disease usa european commission fluarix quadrivalent new influenza vaccine action plan rise threat menhibrix combine vaccine antimicrobial resistance haemophilus influenzae type b modern medicine dependent effective meningococcal group c consumer antibiotic bacterial infection healthcare division launch new increasingly resistant exist product abreva conceal treatment pipeline new skin health category new variant antibiotic describe ribena tailor africa market world health organization virtually dry annual report information gsk bring wealth expertise pipeline product launch programme gain year experience develop antibiotic bn size fund stimulate research discover new antibiotic use term develop country include leastdevelope country identify un currently rd investment country subsaharan africa noneu lowincome information read position statement middleincome country define world bankgsk corporate responsibility report innovative science create value continue innovate create small research team access catalyse innovation case study close science specialist collaboration public rigorous process involve develop multidisciplinary discovery performance private organisation promise idea product approve unit dpus reduce calorie patient use year costeffective possible include sugar content drink idea research invest good scientific opportunity identify project likely unsuccessful far website new medicine example translate terminate investment early research development process recent discovery pattern recognition stage free resource pursue commitment help receptor biology new treatment promising lead consumer healthy choice people work rd autoimmune disease sign partner uk dedicate find new treatment transform approach government public health responsibility offer great benefit research treatment offer speed rd process make deal ribena lucozade drink patient world help significant improvement exist new medicine available patient soon ranges include low calorie effectively option new treatment chronic option lucozade sport lite obstructive pulmonary disease base annual report detail work reduce sugar improve understand patient need calorie content compromise performance nutrition commit cut sugar content readytodrink case study ribena products uk ireland reduce calorie sugar content lucozade energy range speed innovation benefit melanoma patient uk ireland levels rd organisation work diagnostic test identify tumour scientific expertise hard reduce time take new carrying mutation focus develop innovative product medicine market resource conduct trial ribena plus vitamin c submit new medicine regulatory efficiently possible support immune system ribena plus authority seven year rapid development calcium healthy bone identify potential cancer treatment new agent particularly important lucozade revive calorie early development programme metastatic melanoma patient b vitamin improve energy level clear dabrafenib ongoing phase iii trial combination braf inhibitor trametinib therapy dabrafenib trametinib mek inhibitor clinical activity different melanoma treatment metastatic melanoma tumour setting investigate genetic mutation collaborate compound tumour type biomrieux develop robust genetic mutationgsk corporate responsibility report innovative science create value continue focus patient collaboration case study case study guide research essential accelerate discovery new medicine understand patient need vaccine collaboration support scientific catalyse innovation focus patient programme business model collaboration new bioscience hub bring patient gsk site speak directly enter approximately latin america africa rd teams healthcare research collaboration external saw business need help well medicine public private organisation new stevenage bioscience catalyst sbc inspire employee trust science programme latin discovery partnership academia research park joint venture help improve patient life host america gather momentum seven patient insight seminar site programme example partner partner gsk team scientist department business innovation academic institution worldwide develop medicine disease affect skill gsk wellcome trust east theme strengthening develop innovative research region plan extend england development agency patient voice gsk bring new medicine unmet health need programme african country technology strategy board aim foster people include collaborative scientific community drive establish programme investment gsk employee healthcare professional innovation bioscience project underway europe patient patient advocacy group trust science active project north america disease target include locate gsk site stevenage uk representative discuss range brazil seven argentina area huntington disease neurodegenerative million facility offer small biotech topic include preterm labour rheumatoid tropical neglect metabolic genetic disorder severe pancreatitis life science company startup arthritis asthma parkinson disease systemic respiratory disease gsk invest lead multiple organ failure death academic institution access expertise sclerosis melanoma alzheimer disease million year trust science network scientific facility associate provide recording seminar project external partner contribution partner institution multinational pharmaceutical company dedicate area intranet enable develop vaccine treatment target include brazilian council science provide largescale technical equipment technology foundation employee learn benefit neglect tropical disease laboratory research support state paulo discussion disease develop world scientist house building design ministry science argentina malaria polio minimise environmental impact increase fund available million announce plan aeras global tb addition number company new research annually vaccine foundation run multicentre locate sbc set proofofconcept clinical trial test addition gsk pharmaceutical centre innovation cambridge university mase vaccine candidate tb company participate brazilian healthy adult year age government science border work international programme enable phd scientist aids vaccine initiative research vaccine work discovery performance unit hiv longterm project gsk laboratorie uk spain seven brazilian scientist work gsk corporate responsibility report innovative science create value continue open innovation exist treatment tb gsk remain committed share information case study yearsold clinical trial encourage innovation target disease need take month people clinical study register develop world fail complete course hope announce plan enable researcher explore new potential commercial return share datum speed development access detail anonymise patientlevel treatment malaria develop country change essential new fasteracte treatment datum sit result tre canto way think intellectual property disease cause million clinical trial scientific knowledge way work death globally year behaviour open lab provide open innovation strategy design time pharmaceutical company significant advantage promote change gsk sharing public proprietary compound development potential antimalarial support researcher open lab expertise resource intellectual property demonstrate sign activity tb agent important knowhow external researcher follow publication datum twentytwo visit scientist use worldclass facility financial scientific community compound world use facility support access broad range current focus disease inhibit malaria share directly open laboratory tre canto spain pharmaceutical drug discovery expertise develop world adapt research institution world launch project opportunity collaborate open innovation model apply approximately compound open lab portfolio complete active open manner unique area great medical need scientific include malaria box create approve start research environment open lab challenge include infectious rare research partner medicine malaria venture project support notforprofit challenge ambitious project disease alzheimers malaria box set compound tre canto open lab foundation set undertake give million funding gsk commit great chance success share research finding antimalarial activity share million foundation research group world say matthew mcconville postdoctoral screen gsk entire doubling funding independent research researcher liverpool university pharmaceutical compound library contribute information foundation oversee board chemical series million compound compound searchable public database lead scientist support researcher malaria compound inhibit tuberculosis tb bacteria available resource research neglect develop new medicine treat disease publish explore potential identify promising hit tropical disease tuberculosis malaria develop world september new class malaria treatment act start point discovery set wipo research collaboration new medicine tb information private public sector organisation launch proposal project tre canto open lab foundation compound available gsk found member explore potential treatment tb malaria provide grant fund chaga disease leishmaniasis sleep research liverpool university january programme share sickness bill melinda gate new treatment malaria information insight centre foundation launch grand open lab facility spain world health medicine work challenge seek new research idea metap inhibitor tuberculosis save malaria opportunity come centre estimate scientist spend time open lab month work point knowledge pool form roll malaria compound publish wipo researchgsk corporate responsibility report access healthcare aim significantly adapt range sustainable business affordability case study model tailor approach reflect improve access gsk st need country different market lack innovative business model flexible product people access healthcare acute gsk top pricing help people vaccine need world world poor country develop access medicine index medicine need building country market access dcma business particularly emerge market develop appropriate operating unit clear objective increase increase overall volume product gsk top access medicine index product range provide patient access gsk medicine vaccine atmi consecutive sell commitment sustainable vaccine medicine million people time rank access pricing include country expand market medicine foundation examine flexible pricing base countrys affordable price develop presence ensure business pharmaceutical company wealth ability pay define country invest continue sustainable strong improve access medicine world bank unit work country manager gsk develop world quote strong healthcare system business provide holistic integrate index founder wim leereveld tiere pricing vaccine link gross approach increase access reflect national income capita volume order need country dcma score rank unit establish volume highest overall achieve high cap price patent medicine medicine supply leastdevelope score seven category vaccine world poor country country increase nearly access management research product sell leastdevelope country million unit development capacity advancement ldcs price million philanthropy uk category develop country work closely affordability partnership include discount government healthcare provider payer atmi report note gsk invest card reimbursement scheme payment healthcare system understand money company plan patient middleincome country need help ensure product target disease cover index available affordable highlight partnership help uninsured patient develop pathmalaria vaccine initiative mvi country government face develop rtss malaria vaccine austerity measure recommend gsk encourage government adopt increase transparency public policy support differential pricing marketing campaign drug recall example continued support eus tiere pricing regulation work uks industry government forum access medicinesgsk corporate responsibility report access healthcare continue commitment extend treatment benign prostatic hypertrophy fraxiparine partner gavi gsk lead supplier vaccine noncommunicable disease ncds anticoagulant ultiva anaesthetic arixtra longstanding partner cervarix protect woman cancer cardiovascular disease mental health venousthromboembolism vte zeffix gavi alliance fund immunisation cervical cancer affordable price chronic respiratory disease hepatitis b vaccine cap programme world poor pan american health organization grow fast middle lowincome west european average price country price gavieligible country purchase behalf middleincome country information reduce price little tenth develop country latin america approach ncds read lengthy treatment offpatent antibiotic augmentin zinnat develop country caribbean regimen condition certain country vaccine expensive exploring way increase gavi launch world large case study sell small private market ldc affordability introduce small pack size mass vaccination programme offer western european case study researching dose pneumococcal disease pakistan gsk average gavi alliance unicef extend immunisation requirement way combine drug synflorix vaccine pneumococcal disease purchase large volume vaccine patient need separate medication lead cause death child lifethreatene world poor child benefit introduce riskshare model low price measure impact develop country programme rotavirus market example brazil price reduction sale volume pakistan child die million people access tykerb increase significantly reach pneumococcal disease year expect offer secure supply rotarix successful introduction riskshare patient sale medicine protect million child year vaccine low cost help scheme involve breast cancer increase market pneumococcal vaccine expect reach gavi alliance immunise million child patient tykerb assess cut product price increase access gavisupporte country rotavirus rotavirus week respond flexible pricing vaccine synflorix introduce madagascar severe diarrhoea cause kill half million treatment reimburse cost available kenya ethiopia child year child minute vaccine include immunisation price cap leastdevelope previous year provide synflorix gavi responsible million campaign country worldwide hospitalisation clinic visit year country ldc discount innovative financing deliver billion million vaccine reduce suffering world ldc offer gskpatented vaccine dose use mechanism know advance market death rotavirus cause product heavily reduce price price develop country commitment gsk provide minimum cap price million dose synflorix gavi help gsk committed supply gavi support expansion life uk france product sell expand immunisation programme alliance rotarix save immunisation programme nearly uk provide price cover pneumococcal disease develop country vaccine purchase high year offer vaccine manufacturing cost offer protect million child volume long time period reduce cost develop country sustained longterm able reduce price tiere pricing system base gross national supply gavi rotarix dose gavi alliance aim expand capped price apply follow brand income define world bank vaccine rotavirus lead cause rotavirus vaccination country seretide asthma chronic obstructive pulmonary able significantly reduce childhood mortality case study worldwide gavieligible disease copd avamys rhinitis flixotide price dose sell vaccine rotarix synflorix agreement gavi country introduce rotarix asthma malarone malaria avodart demand relatively predictable immunise million child national immunisation programme large volume longerterm contract make significant contribution armenia ghana malawi moldova un millennium development goal reduce tanzania yemen apply individual product line formulation sole supplier market child mortality twothirdsgsk corporate responsibility report access healthcare continue flexible pricing payment plan price accord patient income equivalent efficacy comparator product case study middleincome country example cancer patient hong kong france partner economic apply discount depend committee enable fast patient access gsk flexible pricing approach innovative income level eligible patient epilepsy treatment trobalt pay small pack size payment scheme middleincome country enable people access assess specialist ngo pay performance risksharing model make asthma medicine healthcare provider reimburse cost treatment product help increase volume affordable reimburse ngo turn stop month sell grow market example reimburse gsk scheme offer conditional flexible pricing sale volume avodart treatment worldwide million people introduce tykerb patient structure base result postregistration enlarge prostate avamys nasal spray affect asthma disease benefit expand study comparative trial allergic rhinitis grow account death year include votrient revolade patient respectively emerge market patient assistance programme patient oral medication benefit votrient revolade asia pacific market access pricing treatment option programme help uninsured treatment increase team help local operating company provide slow relief underinsured patient respectively introduction establish appropriate pricing market produce systemic effect medicine need eligible patient patient access scheme expensive inhale version country average national extend cover benlysta lupus patient enrol patient assistance program medication income level warrant list price prescribe gsk medicine reduction affordability remain barrier payment plan enable patient vaccine worth total million december launch patient offer range payment manage cost treatment million ventolin rotahalerrotacap indonesia scheme enable patient afford monthly repayment interest lowcost inhaler use single dose programme include treatment need easily possible example repayment scheme capsule salbutamol bronchodilator partnering ngo include enable patient peru commitment access cancer sell small pack patient brazil access prolia osteoporosis specialty treatment buy needed aim bring discount card enable eligible patient product million patient help government manage bridge access nonspecialty medicine senior citizen disable people market emerge market gsk vaccine access program healthcare cost europe lowincome patient chronic disease asia pacific year gsk access senior disabled patient receive direct discount pick public healthcare budgets immense enrol medicare prescription partner pharmacy pressure european country result ukraine offer asthma patient economic environment tailor addition programme uninsure discount card seretide approach need specific country medicare patient copay year approve votrient work closely government achieve assistance programme help patient metastatic renal cell cancer good result demonstrate value patient satisfy income eligibility requirement access payer healthcare professional taxpayer expensive oncology immunology industry medicine participate discount saving card programme rx access uk example commit patient prescription drug coverage market benefit refund national health service information viiv healthcare lowcost inhal expenditure votrient failed year patient assistance program hivaidsgsk corporate responsibility report access healthcare continue availability product portfolio expansion case study case study product registration access medicine dependent sell medicine vaccine affordability availability right partnering improve health leastdevelope country medicine available right place vodafone mobile health commit make new medicine nutrition rural india patient benefit rd pipeline widely available work improve availability medicine december announce new develop country engage seventy cent population increase product registration new strategic partnership vodafone regulator enable registration india live rural community exist product market seek use mobile technology help vaccinate medicine exist portfolio limit access medicine health advice strategic alliance acquisition child common infectious anticipate year service poor nutrition frequently expand presence african disease africa proliferation mobile include treatment infectious exacerbate health problem area country partnership ngos phone africa offer opportunity disease noncommunicable disease particularly mother child un organisation example create innovative costeffective way asthma depression cardiovascular half child live overcome barrier vaccination rural area india malnourish support objective un commission disease cancer account lifesave commodity woman initial focus new partnership death globally pharmaceutical consumer child oneyear pilot project mozambique healthcare business india join begin extensive catchup establish mobile technology force promote well health programme product registration bring increase proportion child nutrition area build establish product develop vaccinated encourage mother strong reputation horlick brand country particularly subsaharan africa vaccination service support health team offer advice support receive approval product worker improve record keeping community organisation local develop country therapy area enable well management vaccine doctor pharmacie mobile health central nervous system noncommunicable stock successful project create van deworme health camp model replicate disease respiratory antibiotic oncology work local healthcare mozambique scale africa shift approach provider increase access medicine launch new product pipeline zentel worm infestation offer affordable option new drug fesovit iron deficiency treat disease enter market worsen blight malnutrition launch benlysta treatment systematic lupus erythematosus hong kong simultaneously offer measure increase affordabilitygsk corporate responsibility report access healthcare continue local manufacturing strengthen healthcare system year support case study capability building work network education gsk reinveste profit support immunisation nesi local manufacturing increase availability generate world leastdevelope provision funding enable independent support franchise support local economy cut cost production transport product country ldc community programme vaccinology training healthcare worker local medical clinic strengthen healthcare infrastructure subsaharan africa north africa saving pass patient kenya rwanda country primarily train middle east skilled knowledgeable form price reduction community health worker human resource key deliver appropriate strategy expand partnership reinvestment community healthcare service population number joint venture health worker train basic healthcare nesi support peopledevelopment w enit th e ro prn ise e f ta hm ai tl e xh te ea nl dth c c ep sr si v ta ot e technology transfer arrangement help delivery act point contact initiative nesi contribute healthcare rural slum area build capability develop country people remote marginalise improvement quality sustainable franchise system enable local research manufacture vaccine communities near health clinic immunisation programme provide nurse operate basic medical increase market access include new hour day away deliver service low middleincome country clinic know child family wellness joint venture daiichi sankyo develop vaccination diagnose illness administer capacity build education health post provide access distribute prophylactic vaccine japan medicine provide pregnancy support training key partner finance training support biological e lead indian vaccine company offer hygiene sanitation nutritional organisation unicef enable nurse create new health research development sixin advice improve health particularly gavi implement vaccination post rwanda year combination paediatric vaccine woman child reduce programme region addition exist clinic longstanding partnership burden health system manage help strengthen healthcare kenya support half brazil oswaldo cruz foundation case locally system initiative tackle million patient year gsk cover polio haemophilus influenza type b commit partnership hib measle mump rubella rotavirus invest base counterfeit medicine illegal establish initial post rwanda pneumococcal disease profit fund contribute dangerous provide million interest approach technology transfer training health worker free loan enable expansion behaviour reach million people franchise network strengthen health infrastructure year develop country partner harambe entrepreneur alliance fund reinvestment programme fellowship support african entrepreneur deliver partnership work innovative solution micro nongovernmental organisation health insurance mobile technology regional expertise work save healthcare harambe gsk fellowship child west africa amref east attract highly qualified young southern africa care international african entrepreneur asia october programme empower social business venture place develop nigeria rwanda zimbabwe south africa country profit gsk corporate responsibility report access healthcare continue reinvestment programme establish country central african republic sudan afghanistan nepal south sudan bangladesh niger chad bangladesh niger myanmar train community train community health health worker establish volunteer screen child laos community support group sign illness malnutrition cambodia provide essential health promote local health service service health education support people awareness support save child family rural mauritania northeast country care international mali senegal guinea burkina faso guinea strengthen capacity health yemen worker deliver maternal djibouth newborn child health service family planning help benin ethiopia tanzania uganda improve quality healthcare liberia uganda children age sierra leone togo rwanda provide elearne remote burundi professional development save child nurse midwive work democratic republic tanzania congo rural area amref angola mozambique zambia initiative acknowledge sudan split haiti sudan south sudan develop deliver train run trainer course help community madagascar p inr eg ar hm cm oue ns ry health worker bring lifesave healthcare child live earthquakeaffecte region website leastdevelope logne save child haiti lesotho list programme country countrygsk corporate responsibility report disease develop world neglect tropical disease holistic approach work commitment progress date polio malaria partner research new vaccine play lead role partnership donate billionth treatment exist industry gate foundation albendazole tablet fight lf blight world one available affordable result london declaration intestinal worm infection lf lead vulnerable community strengthen healthcare system commitment pharmaceutical company global cause disability intestinal worm government nongovernmental organisation infect million child world aim help control cause chronic infection result advocate adoption public control eliminate neglect eliminate malnutrition impair development policy provide adequate finance tropical disease end decade disease transform mechanism gavi alliance london declaration partner support help achieve world life contribute funding immunisation poor country commit eliminate lymphatic filariasis health organization target deworm global fund fight aid tb lf know elephantiasis guinea worm school age child country socioeconomic development malaria board gavi blinding trachoma sleep sickness intestinal worms endemic donate million albendazole treatment tackle develop country roll malaria partnership leprosy control soiltransmitted helminth lf soiltransmitted helminth found member global alliance intestinal worms schistosomiasis river commit donate eliminate lf help organise blindness chaga visceral leishmaniasis billion year major conference neglect tropical collectively industry supply half billion people disease world bank wilton park drug need country treat meeting malaria expert annual report london declaration antiparasitic tablet country integration new tool achieve zero include scorecard show status complete mass administration death elimination disease publish january treatment neglect tropical disease establish dedicated ntds unit research new treatment accelerate contribution neglect tropical disease ntds threaten invest research global effort tackle ntds billion world poor people ntds partnership prevent work research fund partnership organisation drug neglect perpetuate cycle poverty initial focus work align effort disease initiative notforprofit product partner tackle development partnership little invest prevent disease treatment exist lf treat begin work partnership onchocerciasis schistosomiasis trachoma university dundee wellcome trust soiltransmitte helminth disease develop effective affordable treatment intestinal worm neglect tropical disease chaga disease leishmaniasis human african trypanosomiasis sleep sickness collectively responsible death year develop worldgsk corporate responsibility report disease develop world continue partner army polio produce supply ipv tiere price case study brazilian ministry health country implement immunisation develop vaccine dengue lead eradication polio come step close programme work potentially fatal dengue fever incidence removal india available low cost combination vaccine vaccination save dengue infection increase fold world health organization list country develop world contain ipv life democratic year approximately polio endemic country alongside vaccine disease republic congo billion people globally risk afghanistan nigeria pakistan diphtheria tetanus whooping cough phase clinical trial dengue declare poliofree invest million gsk partner unicef purify inactivated vaccine dpiv begin long history support effort new manufacturing facility wavre programme vaccinate mothers puerto rico collaboration eradicate polio early see key belgium produce vaccine contain ipv baby democratic republic army sponsorship agreement support polio develop emerge market congo drc partfunde new london eradication develop vaccine launch new joint venture child die age centre neglect tropical disease supply oral polio biological e lead indian vaccines children drc risk research joint initiative imperial vaccine opv provide company research development outbreak preventable disease college london london school million dose global polio sixinone combination paediatric vaccine polio measle hygiene tropical medicine eradication initiative publicprivate partnership vaccine combine ipv immunise raise awareness natural history museum lead national government world biological es vaccine diphtheria tetanus community leader promote undertake innovative research health organization commit whooping cough cell pertussis importance vaccination control mapping diagnosis meeting initiative polio hepatitis b haemophilus influenzae type provide refrigeration equipment need common ntd infection vaccine requirement procure b approve enable few injection store transport vaccine soiltransmitte helminth unicef approximately billion child support compliance schistosomiasis impact life dose continue support immunisation enter agreement million child vaccinate measle global population initiative country world uk health protection agency million polio follow research centre declare polio free national institute biological standard record case polio case dedicate ntds opv relatively inexpensive control nibscs nonpathogenic polio case record take orally vaccine distribute genetically stable salkderived polio strain volunteer need train give opportunity research healthcare worker sterile injection equipment potentially develop lowercost manufacturing country polio platform ipv component paediatric eradicate opv live attenuate vaccine combination vaccine long term phase replace technology lead manufacture inactivated polio vaccine ipv prevent component develop country risk polio reemerging vaccine live birthsgsk corporate responsibility report disease develop world continue malaria publish result date confirm rtss promote use exist measure case study help protect african child community investment malaria responsible malaria followup result provide african malaria partnership support local death year mainly child datum provide insight develop ngo programme promote use age subsaharan africa vaccine candidate efficacy different malaria new treatment preventative measure bed net half world population risk parasite transmission setting longterm indoor spray control mosquito disease efficacy impact booster dose resistance current treatment grow atrisk community research vaccine result expect publicly develop new medicine treat available end malaria antimalarial example funding threeyear research vaccine programme amref southeast compound available stimulate malaria year vaccine approve remain tanzania increase use research area malaria key working develop committed price cost production bed net focus tre canto open lab vaccine publicprivate partnership plus small return year halve malaria death path malaria vaccine initiative reinveste research development underfive kenya partnership mvi aid grant bill second generation malaria vaccine vaccines partnership nonprofit save child distribute melinda gates foundation rtss malaria disease develop world organisation medicine malaria insecticidetreate net reach vaccine candidate final stage venture research address people year clinical development pivotal phase iii press need treatment work family health international trial underway seven african country drugresistant strain malaria ghana raise awareness need involve child parasite treatment specie seek prompt treatment malaria malaria predominant asia latin america plasmodium vivax tafenoquine investigational medicine develop treatment relapse prevention plasmodium vivax malaria death year malariagsk corporate responsibility report health wellbeing community fund support programme include develop product financial donation give breakdown type giving improve health infrastructure health local programme hygiene sanitation education medicine gsk donate medicine value leverage core consumer health product donation million cost million capability humanitarian relief response science fund half total give education develop healthcare professional million product donation significant contribution future investment benefit support lowincome patient health wellbeing community bring value business patient assistance program community building relationships trust key usa stakeholder strengthen reputation million product donation cash product inkind engage employee deliver partner americare direct time aim increase impact relief international m world health management partner local organisation support map international project hope total programme design longterm humanitarian aid partner distribute sustainable impact encourage donate medicine country financial give type programme employee involve volunteering include provide supply antibiotic support basic medicine oral hygiene item people affect conflict cholera epidemic niger flood philippine hurricanes global community investment isaac sandy usa total million million compare million million continue inv phase personal hygiene sanitation education programme prevent diarrhoea pneumonia teach child health wellbeing importance hand washing education begin integrate oral health education programme reach million child country provide million donation albendazole commitment eliminate lymphatic filariasis cashgive support programme aim strengthen healthcare infrastructure gsk value product donation cost good believe reinvestment true reflection cost gsk wholesale acquisition cost value cost report wholesaler profit leastdeveloped country standard pharma industry value product donation community investment total value product donation base wholesale acquisition cost milliongsk corporate responsibility report health wellbeing community continue case study case study case study case study partnering improve strengthen empower woman rethink health roma community immunisation infrastructure latin america mean healthy mumbai slum community usa work different ngo support women development partner improve access healthcare organisation pro mujer empower estimate million people begin convene series socially exclude roma community woman overcome poverty living slum mumbai india forum well understand barrier bulgaria hungary romania latin american country risk disease high opportunity build healthy slovakia million roma people year holistic package child fully vaccinate community usa gsk partner lack basic service clean drinking education healthcare financial birthday partner medium company atlantic water sanitation healthcare service include loan start international ngo path mumbai host conversation community business establish threeyear programme government local communitybase health diverse american city train health mediator organisation develop sustainable programme help woman gain access forum philadelphia st louis improve health awareness tackle integrate approach improve education training financial support denver bring hundred high rate infectious disease child immunisation infrastructure increase include loan start small business community stakeholder expert mortality roma community support vaccination level proportion profit local health organisation government range medicine vaccine reinveste family work health post serve business academia discuss regular health check health education health programme help child year old work effectively help family counselling far nearly educate empower build selfesteem raise awareness importance people live healthy life insight gain child benefit woman improve health vaccination provide coldchain storage discussion help shape roma settlement work financial independence lift delivery vaccine use mobile approach local engagement eu government develop new policy family technology record datum send text usa hope help influence support secure longterm funding poverty message appointment reminder local policy decision make health mediator roma community parent end month project half child fully immunise project create blueprint immunisation programme similar setting world child year old reach support health postsgsk corporate responsibility report health wellbeing community continue case study case study case study read online help sick child improve dental support migrant home uk hygiene southern africa communities publish detail online key issue include shanghai china clinical trial develop world help ukbased charity aquafresh dental hygiene programme wellchild help seriously ill child teach child southern africa develop world vaccine production new citizen health care project technology transfer family provide funding brush tooth fund help migrant community ip access medicine nurse provide specialist care work clinic community shanghai china access healthcare develop country support enable child leave group focus raise mother education nearly million migrant pandemic preparedness hospital care home awareness improve oral hygiene population city develop country gskfunde nurse look effectively reach family resident technology transfer capacity build child longterm illnesses aquafreshs range colourful toothpaste permit hukou make difficult develop country provide valuable emotional toothbrush encourage child access basic service work health support family mother child brush regularly partner xintu centre pricing reimbursement raise awareness wellchild life awareness programme community health promotion local ngo change work run promotional gsk briefing noncommunicable reach child specialise public health education disease develop world campaign pack ribena botswana mozambique namibia establish community centre gsk position statement post sponsor wellchild award zambia zimbabwe children playroom classroom development agenda celebrate bravery seriously lecture room provide health education product donation ill child young people uk service migrant dedication health professional community care project financial time citi ingenuity award urban ideas action plan open centre beijing child reach migrant shanghaigsk corporate responsibility report hivaid viiv healthcare global research new treatment transmission hivtb coinfection total country leastdevelope country end clinical trial subsaharan africa country total specialist hiv company viiv healthcare significant underway trial paediatric lowincome leastdevelope country establish gsk investment research support pipeline study african country participate subsaharan africa home people pfizer join new antiretroviral medicine paediatric study include malawi south africa live hiv world viiv provide benefit exist medicine tanzania uganda zambia zimbabwe shionogi focus efficacy effect resistance profile healthcare offer complete antiretroviral recognise urgent need address gap arv portfolio notforprofit price deliver advance december viiv healthcare submit care treatment paediatric hiv viiv country royaltyfree voluntary regulatory application eu treatment care people healthcare expand commitment licensing policy viiv healthcare enable canada dolutegravir investigational live hiv broad integrase inhibitor treatment hiv area paediatric innovation manufacturer generic medicine sell seed fund include firstofitskind public version entire arv portfolio portfolio antiretroviral currently clinical phase asset private partnership clinton health commitment cover market medicine medicine industry viiv healthcare portfolio access initiative chai mylan laboratorie medicine pipeline license preclinical discovery programme limit submit registration new viiv healthcare grant additional lead pipeline partnership hiv discovery tastemaske dispersible abacavirlamivudine voluntary licence bring total number performance unit include early work formulation paediatric use resource recent voluntary identify new therapeutic option limited setting educational grant total licence grant medicine patent pool antiretroviral drug candidate novel approximately million award foundation manufacture supply mechanism action disease modify organisation improve paediatric hiv paediatric formulation abacavir therapie curative medicine research care treatment access partner million patient addition viiv healthcare research team include international aids society justri develop world access low cost generic build new connection collaboration mater misericordiae university hospital version arvs develop viiv healthcare commercial academic amfar treat asia programme mainly supply licensee organisation improve scientific elizabeth glaser pediatric aids foundation viiv healthcare licensee supply understand hiv work improve access hiv treatment estimate billion arv tablet compare cure example viiv healthcare gsk million signal scientist member international million people live cr report key patent lamivudine aid societys hiv cure industry hiv need treatment receiving expire half way mean collaborative group viiv healthcare antiretroviral arv therapy unaid company able continue supply found member collaboration world health organisation aims long require licence viiv healthcare hivaid immunological therapy public increase number million mean future year private partnership launch viiv healthcare commit play reporting volume sale viiv viiv healthcare support collaborative increase access hiv treatment licensee viiv healthcare remain committed addition summary viiv healthcare research trial resourcepoor setting take innovative responsible licensing strategy demonstrate contribution community response understand public health issue sustainable approach programme cover agreement sign february hivaids information available online wwwviivhealthcarecom prevention mothertochild hiv middleincome country lowincome medicine patent poolgsk corporate responsibility report hivaids continue middleincome country viiv healthcare support community case study adopt flexible pricing policy varie affect hiv accord gdp burden hiv epidemic individual country partnership viiv healthcare fund community project improve early infant diagnosis treatment africa incountry company manufacture support people live hiv medicine locally establish global positive action programme june viiv healthcare malawi percentage hivpositive reduce cost treatment st year positive action aim build elizabeth glaser pediatric aids foundation infant month old initiated build local manufacturing capability capacity communitybase organisation egpaf begin partner twoyear art grow baseline partnership binnopharm russian enable grassroots community action project lesotho malawi swaziland august largely pharmaceutical company enable local address stigma discrimination improve early infant diagnosis improved caregiver followup secondary manufacture viiv healthcare positive action child fund pacf treatment eidt services expand staff ancillary staff train support medicine people live hiv russia award total million local capacity strengthen infrastructure viiv healthcare example project aim improve health project support effort strengthen lesotho introduction integrate wellbee woman child family national health system long term prevention mothertochild transmission usa viiv healthcares patient affect hiv viiv healthcare ministry health moh pmtct paediatric care treatment assistance programme help uninsured country integrally involve commit million fund service ensure hivpositive lowincome patient access hiv medicine project rollout continuity assure project country include mother infant continue patient saving card programme continue sustainability minimal renew support grassroot community receive care nurse provide saving eligible patient external support project site project make tangible difference pmtct cascade outofpocket prescription cost country altogether positive action project site show result percentage hivpositive start rate reimbursement pacf community grant disburse encourage increase early infant diagnosis infant initiate art climb increase viiv healthcare local operating rate treatment uptake nearly help moh medication month viiv healthcare company give support hiv infant test critical identify infect child previously lose support welvista nonprofit programme community organisation find age week old referral distant art service facilitate access hiv medication wwwviivhealthcareeffectcom infant test positive hiv swaziland paediatric hiv training nearly people waiting list initiate antiretroviral therapy art curriculum develop support government aid drug viiv healthcare integrate assistance program exist moh nurse training ensure sustainability government ownership result project advocacy moh swaziland nurse code practice amend allow nurse initiate art nationwide improve patient access art bring art service close population needgsk corporate responsibility report behaviour focus researcher able access detailed anonymise patientlevel datum clinical trial read section overview ethical standard principle sale marketing work healthcare professional research practice manufacture supply chain public policy patient advocacy approach tax gsk corporate responsibility report behaviour focus access patientlevel datum clinical trial deliver success valuable researcher want opening learn exist medicine improve important achieve patient care number year gsk access respond external request patientlevel interest patient data casebycase basis go forward trial datum allow researcher request anonymised consumer drive patientlevel datum publish clinical trial approve terminate medicine value transparency respect integrity enable researcher examine trial datum closely combine datum patientfocus different study conduct research take commitment openness transparency clinical trial step publish summary result value back clear code conduct robust compliance perceive positive system training support help employee negative research trial gsk clinical study register right decision standard extend supplier contractor clinical trial result summarie available site receive average ethical issue associate research visitor month early development rd manufacture sale product outline plan add clinical relationship healthcare professional patient regulator new plan acknowledge study report register future need honest transparent address commitment individual participate research trial put information public domain people individual participate hope bring advance healthcare new plan acknowledge operate research trial commitment reflect desire ensure contribution lead open challenge discussion afraid change health gain safeguard work reflect societys expectation confidentiality ensure datum valid scientific reason independent panel review request allow access researcher able submit request dedicated website approve information provide secure environmentgsk corporate responsibility report overview glance ethical standard principle commission independent commitment external perspective review drug safety process revise simplified code conduct detect adverse event c ontinue drive valuesbase approach easy employee understand life cycle product sale marketing practice apply gsk value behaviour world interest consumer andrew witty gave keynote patient core speech annual pear business manufacturing supply chain continue ensure interest school partnership lecture safety patient consumer give valuable insight establish human right steering group paramount importance way senior manager oversee approach design undertake clinical trial mean responsible product quality assurance leader world intense connectivity apply un guide principle business human right monitoring report adverse event enforce transparency ask ongoing product usage position authority rigorously challenge need animal go power study work minimise impact ve hand entrust animal welfare invest drive message development alternative study organisation like gsk undoubtedly sale marketing sharing animalbase datum challenge essential create reach settlement address un guide principle truly valuesbase business government resolve longstande add anticounterfeite technology human right business legal issue sale product china result significant operation supplier relationship marketing practice reduction number report fake transparent possible gsk medicine reach market clinical trial datum include publish clinical study report patientlevel datum outcome trial medicine conduct gsk appropriate research practice process make available researcher public policy patient advocacy access anonymise patientlevel datum commit provide access anonymise scientific enquiry trial datum publish clinical trial publish list membership trade authorise terminate medicine association primarily represent demonstrate gsk interaction addition disclose result pharmaceutical consumer product patient advocacy group political research publicly accessible clinical vaccine business national regional stakeholder conduct appropriately study register website receive international level ethically transparently professor david grayson average visitor month director doughty centre corporate responsibility cranfield school management httpwwwsomcranfieldacuksompresearch researchcentresdoughtycentrehomegsk corporate responsibility report ethical standard principle ethical conduct priority revise simplified code living value scientific engagement conduct easy employee gsk failure uphold understand apply gsk value focus integrate valuesbase scientific engagement policy establish high ethical standard behaviour number key principle culture gsk employee survey explain principle erode trust company previously cover policy result reflect effort engage external scientific activity integrate code available integrate valuesbased culture gsk advisory board publication scientific product damage language support new respondent state understand congress medical education reinforce reputation result online policy resource centre provide constitute ethical business practice clear distinction scientific information support training employee conduct job promotional activity gsk ensure financial relate topic revise code annual business ethic certification scientific activity carry way legal consequence publicly available website manager confirm compliance reflect value establish internal quality assurance group monitor gsk employee access whistleblowe code conduct revise implementation practice mechanism use advice relaunche report suspect case misconduct manager ask undertake bribery corruption anonymously require train new approach help zerotolerance approach bribery reinforce role leader inspire corruption set prevent right behaviour create safe environment corrupt practice policy antibribery employee speak key leadership corruption programme review development programme update audit risk committee annual basis reflect principle live gsk value performance review anti day decision make bribery corruption oversight committee medical governance meet monthly team help implement policy system principle policy accountabilitie know medical governance design sure research activity conduct recognise standard line value responsibility medical governance sit chief medical officer organisationgsk corporate responsibility report ethical standard principle continue human right management human right embed privacy bcrs comprise element business include include internal corporate policy commit uphold un data protection security continue standard training programme audit universal declaration human right employment standard cover topic high priority global privacy global privacy office develop oecd guideline multinational enterprise diversity equal opportunity health principle ensure personal datum roll robust privacy awareness core labour standard set safety collect process transfer training programme include international labour organisation ilo supplier standard audits help store appropriately securely line training module global privacy gsk signatory un global compact promote human right supply chain legal requirement commit principle bcr standard voluntary global standard human right exercise high standard integrity labour environment anticorruption deal protect personal datum audit assurance group system protect right people take require employee supplier perform independent audits support guide principle business clinical trial comply global privacy principle compliance privacy policy human right endorse united effort improve access healthcare global privacy office oversee privacy standard applicable law nation human right council help promote right health process communicate good practice addition implement datum review policy process gsk privacy monitoring programme sure reflect principle business unit enterprise global establish human right steering read online human right statement await approval uk privacy office identify key privacy group senior manager oversee information commissioner office control include monitor approach steering group include activity embargo country bind corporate rule bcrs submission program ensure consistency datum representative function human continue implement collect monitoring activity stakeholder concerned resource procurement chair critical element bcrs require uk give global privacy office analysis business activity country target senior vice president governance european data protection regulation trend determine internal sanction law cuba north korea ethic assurance transfer personal data affiliate locate control effective iran sudan syria share uns belief plan place address gap identify outside european economic area people deny access review approve fully implement bcrs medicine regime operate improve efficiency transfer country aim provide medicine personal datum company vaccine country need increase confidence security wish purchase observe personal datum entrust applicable sanction export control scope bcrs cover personal datum comply disclosure requirement hold employee research subject iran threat reduction syria human healthcare professional partner rights act researchgsk corporate responsibility report ethical standard principle continue compliance address misconduct maintain build strong track record breach external code compliance additionally continue manager ensure compliance contact focus manufacturing quality see collect information breach external company policy area responsibility ethic increase disciplinary number industry government promotional code corporate ethic compliance compliance channel mixture allegation good manufacture practicegood commercial business find department investigate suspect legal misconduct request information distribution practice gmpgdp category breach external code time ethical policy violation guidance time period category compare time employee report concern suspect remain broadly consistent time investigate breach external code step prevent reoccurrence case misconduct variety employee employee remain company include retrain corrective channel include confidential speak discipline policy violation follow policy violation receive retrain action include disciplinary action integrity line available increase monitoring support different language dismiss case retrain extend employee standardise reporting channel agree leave company voluntarily colleague prevent make employee base report know separation similar mistake consistent way refresh disciplinary action include awareness campaign encourage employee document warning type policy violation help report concern policy violation relate fully investigate suspect breach breach sale marketing code confidential manner disciplinary resulted dismissal action include dismissal separation document warning appropriate violation policy report audit risk committee believe increase see board increase focus attendance payroll category violation attendance payroll respectively attendance gmpgdp issue mainly report code conduct manufacturing business marketing promotional activity policy violation implement tight control ensure total violation gmpgdp relate good manufacturing practice good distribution practicegsk corporate responsibility report sale marketing goal drive value reflect commitment consistently reinforce code policy issue question originate high standard launch new global training compliance procedure different era company base approach sale code practice promotion customer make sure way pay sale team ignore learn marketing practice interaction apply reinforce value year usa world interest employee involve sale marketing settlement government take action level party act behalf company enhance improved consumer patient cover area provide information agree payment procedure compliance marketing core apply fee service payment healthcare billion relate investigation sell base value sale consumer professional sample hospitality grant usa longstanding legal issue transparency respect integrity patient donation state market sale marketing practice condition focus necessary remove product promotional activity conform high settlement enter corporate employee engage misconduct marketing prescription ethical medical scientific standard integrity agreement cia office broaden ability claw base valid scientific evidence comply inspector general oig department remuneration senior management medicine vaccine applicable law regulation health human service event misconduct healthcare professional industry code sale marketing build exist comprehensive hospital government employee train compliance programme revise code criminal plea relate aspect employee party involve marketing paxil paediatric use sale marketing follow wellbutrin certain use failure business area commercial practice policy include information initiation marketing code global status certain avandia study periodic scientific engagement principle annual report submit food drug administration civil portion voluntarily implement settlement new system evaluate compensate admission liability admission sale professional usa work criminal plea paxil wellbutrin directly prescribe healthcare professional resolve allegation separate new system call patient basis investigation sale incentive compensation primarily sale market company product competency customer evaluation second certain nominal pricing overall performance business allege bundle sale arrangement number prescription generate company promotion currently explore submission avandia learning patient programme view inform global approach sale incentivesgsk corporate responsibility report sale marketing continue implement directtoconsumer marketing marketing child corporate integrity agreement prescription medicine guideline advertising child date employee cover advertise prescription medicine prohibit advertising child cia complete total hour directly consumer usa local legally mandate minimum age training requirement gsk board new zealand directtoconsumer dtc inappropriate market director vendor advertise prescription medicine drink product year old train gsk manager permit market product deliver appropriate nutritional complete additional compliance training benefit child country improve update dtc advertising usa govern product market promote policy procedure establish dtc communication policy base drink product responsibly ensure control centre excellence enhance phrma guide principle direct advertising sponsorship message monitoring business establish consumer advertisement appropriate nutritional benefit risk mitigation plan prescription medicine dtc sport star sponsorship important brand market product advertising usa review legal lucozade sport guideline state regulatory medical specialist new reporting progress regularly people set appropriate dtc television advertisement submit government example sponsorship food drug administration independent audit appeal solely fda review comment prior complete implementation cia child age broadcast advertise erectile requirement work not end dysfunction medicine television step continue raise awareness revise policy practice pharmaceuticals business monitor compliance live receive notice violation value day warning letter fda advertising promotiongsk corporate responsibility report work healthcare professional doctor healthcare believe hcp healthcare read work uk march gsk organisation hco work hcp global code healthcare company start report professional hcp fairly compensate service expertise practice promotion customer annually payment hcp valuable partner gsk provide payment interaction online previous year aggregate level provide scientific excessive transparency cover payment hcp advise inducement reward prescribing consulting service financial support medical expertise product clear standard align committed publishing sponsorship grant donation insight patient care international regional code practice payment hcp hcos healthcare organisation appropriate country law regulation believe partnership country plan publish govern payment help fundamental operate complex challenging task information hcp payment number safeguard risk need align system country specific reporting progress medical science work hcp hco number country multiple currency requirement introduce help meet patient way meet different regional country come year continue report requirement public health need conduct research hcp conduct clinical support work transparency introduce achieve introduce research behalf act investigator countrie industry association new process gather datum effectively responsible oversee study government establish specific guideline accurately business expertise insight resource help disclosure develop deliver new patient treatment year started continue work publish publish information country advise consult hcp provide global figure aggregate level hcp support introduction locally agree expertise insight gsk advisory panel payment include advise consult government industry association standard example specific disease identification financial support sponsorship grant symptom diagnosis usa payment hcp donation conduct research speak behalf product individual level speak consult ukbased company use uk disease therapy area relevant publish standard basis approach begin disclose payment institution report global figure financial support sponsorship hcp act lead investigator provide hcp help attend separately publish information assist clinical research study local international meeting community investment grant product q align report new scientific medical andor educational donation grant government requirement support limited registration fee patient advocacy organisation read online reasonable travel meal accommodation australia publish aggregate grant donation payment hcp hco response unsolicite request actively support adoption hco support healthcare medical industry association standard scientific research receive service privilege benefit returngsk corporate responsibility report research practice patient safety priority aspect research raise ethical conduct clinical quality review inform consent concern include relate animal assurance assessment confirm documentation procedure paediatric stage research clinical research use emerge conduct trial reflect standard include study review lead enhance new product go technology aim address procedure identify variation relevant investigator site conduct gsk sale open transparent practice regularly local law simplify inform sponsor clinical trial represent engage academic scientist regulator consent language work disclose site provide primary policymaker stakeholder data regulatory approval base transparency clinical research result clinical research clinical research gsk process include datum quality commit reporting result high ethical quality clinical trial healthy volunteer protocol development clinical clinical research evaluate medicine standard apply patient enable assess investigational study report vaccine irrespective research development medicine potential evaluate outcome perceive positive negative contract research organisation carry medicine approve believe fundamental take place clinical trial behalf marketing conduct trial accordance advancement medical science help good clinical practice gcp gsk local operating company involve inform prescriber patient guideline develop international clinical trial activity finding relate medicine conference harmonisation base new drug application nda annual principle contain world medical report review prior submission association declaration helsinki post result research food drug administration ethical principle medical research publicly accessible clinical study register fda provide update status involve human subject website receive average study complete progress visitor month end trial protocol review ethic addition investigation conduct contain result committee independent gsk response suspect irregularity summary post launch member public medical investigator site contract research organisation early announce plan professional scientist ethic local operating company fully expand register include clinical committee power reject stop investigate concern issue identify study report clinical trial corrective action appropriate seeking publish research result training auditing clinical research independent regulatory authority paper peer review scientific journal employee complete training perform inspection gsk commitment gcp undertaking role relate investigator use conduct clinical submit article publication gsksponsore clinical research trial october announce new gcprelate training activity commitment help researcher access represent successful anonymise patientlevel datum completion elearne module clinical trial instructorle coursegsk corporate responsibility report research practice continue clinical trial develop country trial highlight know oasis patient safety pharmaceutical company collaborate clinical trial essential ensure investigate gsk product fondaparinux journal editor medical innovative vaccine medicine arixtra prevent repeat heart attack medicine potential risk publish insight practice initiative deliver treat disease pneumonia set run study benefit takes identify step improve credibility cancer diabete important purchase study medicine arixtra medicine experience effect industrysponsore research result vaccine medicine evaluate pharmaceutical company important identify evaluate publication recommendation broad population country study underway give minimise safety concern ensure overall closing credibility gap report country india patient enrol receive benefit medicine outweigh risk industrysponsore clinical research regulatory authority require local trial medication take view trial safety effectiveness new medicine highlight opportunity improvement run medicine license able continue demonstrate clinical trial cm g aiml ls la n k p rn ei cy p sra u r la l f tc n sttt tuih pc ce e uls biee n ls ia n cr c ae nl ldua ql dr p ue un ea b sd g tl iit oc hc e v ae e nr ne e dd tw dt oo mt reh en ai sn ku e r e w dr ece avo yer g u l nonn opi tic e n bl gt en h ci aac sta u dl r n u et tr vn ri ea e ois sn pw g w eo dc hr l el cd n r aew n c hi bele et l r ha hn l ad ss le lw r en v ne gce in g w gc will oae n os r ce u cv c n li ite ndew u ice ad tn le pddh r ae w ac cfi e c trn ie crd edsi sn int tg agss nfi tf de ado r nt dh er rt n u ahti io e not u au l yi t wm r nb ae uhraf meo er k nr bee n eat n di r n p se g rw oo f ds p po ur ao om c ttd n eeu il nsypc bt b ss e e ic w ndia b gn e el te ue hb sce ai etd da ee dp b pep yf ff l le ae iv c cr g es ad e spa f p aro e nrr v dve ar ly matter world clinical trial site study process help detect act trial place safety wellbee bhopal india site gas adverse event patient participate trial disaster gsk number priority conduct intend run clinical study bhopal global safety board make decision clinical trial high scientific site bhopal inspect product safety issue remit ensure ethical standard follow strict indian regulator report conclude safety focus product international regulation guideline study generally run accord development review gsk product concern raise international good clinical practice standard market board chair conduct clinical trial india inform consent obtain chief medical officer compose senior concern relate gain approval participant physician scientist trial ensure proper inform consent safety clinical trial participant improve patient safety system provide compensation trial paramount importance create internal medicine risk participant appropriate concern conduct clinical management advisory panel senior gsk trial seriously continue review staff act forum share information procedure ensure conduct good practice company sponsor clinical research high possible scientific ethical standardsgsk corporate responsibility report research practice continue pharmacovigilance external initiative improve animal research case study pharmacovigilance relate understand patient safety animal study remain vital reduction adverse effect medicine work government official industry work partnership research case commission independent partner policy maker improve method demonstrate accelerate standardise review drug safety process safety system medicine vaccine effect potential new medicine live clinical development confirm gsk high standard detect involve body test human animal adverse event life cycle product programme include research provide vital information gsk help create new partnership provide input development cardiac safety research consortium cause disease speed development medicine pharmacovigilance regulation introduce collaboration industry regulator develop regulation require test improve standardize clinical european commission raise public academia improve cardiac safety new medicine animal development practice transcelerate confidence safety monitoring drug device development evaluate clinical trial country biopharm inc joint initiative provide training gsk employee publish paper lead author require additional animal testing pharmaceutical company focus regulation share datum lead participate medicine approve use solution enhance patient safety reduce research project cost streamline clinical development protect partner european project ultimately gsk like benefit gsk involve area work manage european medicine research apply human transcelerate agency look improve need animal testing develop industrywide standard pharmacovigilance technique believe achieve foreseeable approach riskbase monitor future animal research remain necessary clinical trial order enhance patient european programme pharmaco commit act ethically safety ensure quality datum vigilance pharmacoepidemiology provide animal health wellbee launch share portal investigator new venture help establish involved trial streamline access provide training improve practice animal critical information pharmacovigilance student research welfare march introduce standardise good clinical healthcare professional create office animal welfare ethic practice training qualification strategy oawes lead chief investigator recognise veterinary medicine new office participate company responsible develop reviewing partner clinical datum interchange policy oversee humane standard consortium develop standard responsible use animal gsk current support exchange clinical trial oawes initiative look animal datum priority disease area science modelling robust establish reliable quick source help provide well analysis datum gather quality comparator drug use animal research increase clinical trial enhance patient safety use nonanimal research alternative accelerate trial timelinesgsk corporate responsibility report research practice continue apply principle study encourage rs culture regular performance percentage change animal use conduct external contractor training staff involve care use number animal compare key driver animal use behalf carry animal raise awareness rs low main driver gsk facility past year encourage good practice recognise animal use rd investment vaccine animal quality assurance group assess employee significant sale increase period care welfare programme advance implement rs contractor supplier organisation animal welfare award animal use decline compare vast majority meet yearonyear decrease core principle animal welfare respond enter number partnership reflect change research priority few recommendation improvement help reduce refine replace animal vaccine require testing animal animal care programme occasion research include batch release continue focus decide work contractor signing agreement simulation plus rs initiative animal gsk facility animal contractor behalf gsk choose adopt develop software simulate animal research include rd investment plus vaccine sale recommendation clear absorption drug skin research carry contractor mice figure normalise year datum formation glaxosmithkline datum include animal research conduct external contractor follow site visit human animal potentially number fish research model behalf datum unavailable commit continuous improvement reduce experimentation increase example zebrafish rs participate launch crack base screen evaluate assess specie gsk animal research goal use animal initiative organise national centre compound efficacy infectious scientifically necessary use replacement refinement disease neurological therapy area ott hh ee rr r odent scientifically feasible minimise pain reduction animal research nonrodent account rabbit distress scientist apply connect scientist different discipline number animal og n human primate rs principle biomedical research encourage innovation rs animal use nonhuman primate ferret farm replace animal research support association assessment bird method possible accreditation laboratory animal care international advance standard reduce number animal mouse animal welfare china organise fish provide information give conference help translate guide rat precision care use laboratory animal guinea pig refining technique minimise pain pig goat sheep distress maximise animal welfaregsk corporate responsibility report manufacture supply chain effective responsibly year spend billion supplier standard improve ethical labour health good service supplier safety environmental practice current manage supply country party code conduct define collaboration initiative include provision distribution system expect supplier ethical conduct common preaudit questionnaire joint essential high ingredient material buy antibribery practice labour practice share audits help reduce supplier fed network protection human right environmental duplication make compliance quality product right gsk manufacturing site health safety management interaction straightforward supplier place right time country manufacture nearly gsk employee new supplier accept product produce billion comply principle code supply chain performance patient rely package annually meet quality standard conduct environment health supplier deliver value people work global business procurement team safety ehs audit exist manufacturing supply gms division engage exist supplier raise awareness potential supplier good cost operating outsource term code reinforce principle audits assess supplier asia responsible manner production cost manufacturing supplier provide finish riskbase approach determine extent supplier ehs audits partfinishe product area engagement supplier higherrisk exist potential supplier need ensure high quality responsible supplier identify base critical manufacturing product supply chain risk america pose patient business supply europe interrupt fail meet standard asia risk supply chain integrate africa overall risk management compliance total number oversight process audit significant supplier conduct regional distribution total spend supplier audits assess environmental health number type supplier audit ehs exist potential supplier safety governance risk management significant gap identify type supplier america europe asia total recommend use consultant support primary raw material intermediate supplier make improvement suspend pharmaceutical ingredient restrict supply significant improvement contract stop work supplier manufacturing decide work potential new supplier pharmaceutical formulation europe collaborate manufacture consumer healthcare excipient active company sector raw material asia pacific pharmaceutical supply chain initiative psci africamiddle east aim improve security supply latin america japan reduce reputational risk help suppliersgsk corporate responsibility report manufacture supply chain continue conduct few ehs audits overall begin map risk payment term supplier diversity result revise audit supplier manufacturing site help well strategy prioritise supplier plan potential interruption supply change standard payment term small company own woman critical business undertake engage property insurer fm global supplier uk people belong minority group indepth audits supplier involve review risk supply continuity term provide payment represent supply multiple site visit include abovesite key supplier supplier day month follow chain large company gsk believe governance risk management control assess expiry day receipt small diverse business significant believe approach contribute supplier invoice potential meet procurement need well relationship supplier case study greatly value relationship bring value community job significant sustainable improvement supplier understand creation revenue generation eh audit finding supplier year collaboration pressure cash flow financing source diverse supplier benefit occur mainly emerge market face small company time help comply regulation include significant deficiency design year connection divis uk willing review market usa encourage operation safe plant equipment laboratory india celebrate new payment term supplier innovation expose poor management flammable liquid identify micro small new perspective fresh idea supplier inadequate fire prevention control medium size enterprise sme define diversity programme lead usa sign contract measure additional gap identify european commission support procurement team divis supply ingredient zantac area compliance regulation willing review new payment term worldwide usa spend small drug treat prevent ulcer management change emergency response supplier fall category diverse supplier increase stomach intestine quality preparedness safe system work loss ehs technical team work diversity supplier define relevant key sponsor preventioncontinuity planning control closely divis manager develop legislation addition offer range participant msduk conference exposure chemical agent understand requirement supply chain finance option supplier diversity london uk supplier total supplier critical finding support improve procurement team large company audits result supplier quality environment safety system supplier change bring ethnic stop specific process cause divis strong focus put profit payment term little minority business listen presentation concern risk remove community activity impact submit invoice network currently commercial village near manufacturing facility end month pay agreement include build library pay supplier fast customer supplier china teachers local school pay change working bring robust procedure horticultural train local farmer payment term supplier consistent group reduce complexity addition strategic audits past year divis grow provide certainty supplier strength company audits contract manufacturer pay business focus uk final product conduct ehs supplier unanimously feed usa staff business particularly india important ensure suitable standardsgsk corporate responsibility report manufacture supply chain continue anticounterfeite use technology combine gsk anticounterfeite activity strategy work custom decrease number counterfeiting pose threat authority seize counterfeit product report counterfeit incident read online patient consumer health provide custom official information attribute combination business threat gsk product train identify effective preventative measure publish detail online key pharmaceutical company counterfeit helped train serialisation programme china issue include work regulatory enforcement custom official china malaysia robust investigative enforcement gsk antibribery corruption handbook agency address global problem vietnam take regional training strategy lead significant gsk antibribery corruption guideline determine provide way patient session organise world customs increase raid action party check authenticity product organisation wco west east africa cloning technologies stem cell research disclosure clinical trial information example follow pilot nigeria wco launch initiative call gsk anticounterfeite activity care welfare treatment animal introduce anticounterfeite interface public member encourage role transgenic animal measure product kenya exchange information counterfeit number biomedical research tanzania code include product pharmaceutical industry caf sr ee sport use nonhuman primate nhps pack send text message tollfree custom body gsk number discovery development medicine number mobile service look code company sign help pilot raid vaccine send verification text system number counterfeit healthcare product arrest consumer product genuine pharmacovigilance initiative receive george didomizio significant seizures industry award usa recognition result cooperation china company effort business partner operation lead raid underground project prevent spread facility guangzhou seizure counterfeit medicine include counterfeit gsk antibiotic tablet intend west africa china introduce separate case china operator capability serial number pack counterfeit factory guangdong pharmaceutical product allow province sentence lengthy jail term electronic monitoring patient safety fake different medicine value purpose chinese government include dose system result serial number panadol caplet intend middle east introduce pack heptodin medicine combat hepatitis b lesson learn technology china help implement similar initiative worldgsk corporate responsibility report public policy patient advocacy public policy goal demonstrate application new incentive antibiotic moment significant regulatory interaction political stakeholder research increase staff level reform implement andor advocacy work patient advocacy group conduct training rare disease therapy plan eu china valuable contribution appropriately ethically transparently advocate reauthorisation call g government develop debate issue impact provide clarity approach pandemic allhazard preparedness act incentive reward product lower develop set criterion guide public health business improve preparation public environmental impact supportive choose public policy group health emergencies usa public procurement policy influence regulation work advocate support safe dose act trade association membership aim advocacy work support commitment strengthen usa law enforcement responsible approach access innovation explain system fight medical theft protect member trade industry health section association membership group guide value patient risk associate resold support efficiency effectiveness key public policy engagement steal improperly store medical protect interest patient public policy work link provide list include follow product include medicine reentere membership trade association supply chain usa focus primarily represent pharmaceutical consumer transformation usa healthcare work trade association ensure product vaccine business national system submit comment propose change european regional international level list federal agency implement commission datum protection regulation update regularly affordable care act sign guarantee appropriate level privacy political contribution law comment process patient study participant successfully advocate change impede meaningful biomedical research corporate political ensure appropriate access patient urge european union head state contribution implementation law continue find sustainable approach control employee political action committee decade significant pharmaceutical cost minimise provision come effect effect austerity measure usa employee choose engaged federal state availability medicine personal political contribution government policymaker healthcare gsk employee political action committee professional payer ensure law advocate establishment federal pac facilitate voluntary political prioritise quality encourage valuebase drug regulatory authority pakistan contribution eligible employee healthcare system maintain incentive allow drug regulatory accordance federal election pharmaceutical innovation support process start function campaign act gsk employee access medicine vaccine nearly year inactivity pac contribute republicans advocate passage food drug work european chinese industry democrat candidate run administration safety innovation act authority strengthen euchina state federal office fdasia usa allow regulatory cooperation alignment improved process review druggsk corporate responsibility report public policy patient advocacy continue lobby expenditure patient advocacy work patient group state case study thing country cost associate lobby eu patient group nonprofit organisation nominate senior member staff responsible institution range found patient caregiver family lead coordinate patient advocacy european patient outline european member health professional activity general manager academy therapeutic transparency register figure include important stakeholder engage country meet patient group innovation run brussels advocacy office salary healthcare provider government year external event travel accommodation medium patient promote improved consulting cost educational material treatment service patient publish information work involve creation take account proportion campaign issue affect patient patient group online europe asia european patients academy employee time spend represent gsk caregiver life carry research pacific emerge market region therapeutic innovation eupati interest eu institution exclude trade cause potential treatment information support patient patientle consortium association membership fee specific condition group work globally include detail organisation increase capacity funding receive patient effective advocate usa spend federal relationship patient group help adviser clinical trial regulatory lobbying activity well understand patient need voluntarily disclose funding authority ethic committee usa federal lobbying register illness guide rd turn support website detailed eupati provide include cost salary benefit support help patient opinion hear information gsk australia canada seven language european employee register lobby find website provide fund patient group help country educational material government use lobbying consultant daytoday run cost define patient advocacy leader summit research development process support lobbying contact plan event activity support include year patient advocacy leader medicine create public library activity research run gsk educational assistance training staff summit pal bring patient medical rd member washington dc government affairs office eupati consortium contribute collaboration disease awareness advocate discuss health policy support staff portion trade expertise staff time funding prevention project develop new skill way expand association fee associate federal lobbying influence usa gsk employee relevant party national pal washington dc work patient group follow regional pal country guideline standard operating procedure focus patient advocate role sop example limit implement healthcare reform funding provide patient hold pal bulgaria finland group overall funding state netherlands germany portugal slovakia relationships patient group middle east africa regional pal link promotion product qatar excess people provide training employee represent organization understand requirement country participate european operating company pal require apply new minimum standardsgsk corporate responsibility report approach tax business increasingly understand responsibility pay take decision centralise transfer pricing line oecd appropriate tax time pharmaceutical intellectual property guideline base transfer pricing policy challenge ensure responsibility shareholder product inventory ownership uk arm length principle support contribute financially efficient deliver help decrease administrative transfer price economic analysis tax system society sustainable tax rate support effort complexity involve multiple owner report worldwide nature ensure company appropriately intellectual property business operation mean rd operate transparent tax affair deliver supply chain working manufacturing operation centre provide information manage capital efficiency number key location consequence crossborder supply route tax management contribution substantial change possible necessary ensure supply medicine principle policy business employment presence introduction new patent box tax rule numerous endmarket complex country globe pay uk government rule significant tax include corporation uk attractive place locate ip tax haven engage artificial business taxis tax associate investment decision centralise ip tax arrangement business employee example total fund rd uk mean commercial substance policy year pay approximately medium term expect pay use location substantial billion corporation tax globally corporation tax uk business presence substantial local value generate sale pipeline business presence vast majority global corporation tax charge product create uk territory operate core profit approximately billion subject uk tax business office sale force manufacturing group tax rate profit rd facility local distribution mean corporate tax relationship tax authority gsk seek product contribute economic core profit world maintain open positive relationship development create share value amount nearly quarter total government tax authority worldwide region business core profit year welcome constructive debate detail corporate tax charge taxation policy hold bilateral internal process robust internal year set annual report discussion hm revenue custom policy process train compliance hmrc uk internal revenue programme ensure alignment pay considerable tax uk service irs commercial business meet tax give group sale generate term centralisation obligation audit risk committee country significant ahead time agreement tax payer proportion global corporate function pharmaceutical intellectual property ip board responsible approve tax authority appropriate transfer pricing methodology uk refer result tax strategy management certain transaction fix period time rd manufacturing activity agree enter bilateral advance pricing underlie principle transfer pricing locate uk addition corporation agreement irs hmrc company group act tax profit generate employment independent enterprise mean company provide long term certainty appropriately reward asset employ value activity create subject risk assume enter intragroup transaction authority gsk tax treatment ensure profit generate tax country number uk taxis include cost relate value arise appropriate reward consider reward indirect tax employment taxis obtain party know arm length principlegsk corporate responsibility report people people section overview talent development focus inclusion diversity engage employee pulse programme give employee like health safety wellbee megha chance contribute expertise reward recognition widen horizon work nonprofit organisation case save child read gsk corporate responsibility report people focus pulse programme give employee need people develop chance contribute expertise give develop leadership skill widen skill appreciate different perspective horizon work non people profit organisation highly motivate engage chance nearly employee take opportunity work time resilient nonprofit organisation charity month fund gsk megha marketing gain people attract good team india undertake threemonth assignment save child help thrive individual aim ensure work charitys digital medium value support empower successful personally team expertise help professionally want feel proud work save child communicate company work difference work raise awareness issue address gsk strive inclusive accessible attractive employer pulse assignment give megha pulse give people background global footprint change opportunity apply skill opportunity work ensure continues reflect workforce contribute cause feel strongly impact megha marketing clear value govern business responsibly little way experience help share story child strong public commitment value life transform megha work save child ask employee live embody value gsk marketing team india reinforce train communication return gsk megha able bring passion experience recognise reward performance apply work focus help employee remain healthy resilient well patient save child see increase donation result management health safety programme design raise charitys profile online improve work environment engage public social mediagsk corporate responsibility report overview glance talent development people employ emerge commitment market asia pacific japan region recruit graduate globally make represent total workforce c ontinue promote inclusion diversity e xtend volunteering opportunity progress target recruit globally gsk bring positive change graduate year community global health continue create work environment provide individual development inspire people grow perform healthy resilient way launch project search uk help empower employee country group young people learn volunteer nonprofit organisation disability transition education country pulse assignment world work gsk external perspective employee engagement gsk pioneer business disability future challenge ensure global employee survey say proud work gsk base forum vision gsk worldwide engage participation equal level make easy employ business disabled applicant employee survey disabled people company remain stakeholder meet need committed focus disability disable old patient new product global level organisation develop package wide business community gsk act trailblazer inclusion diversity health safety wellbee pilot project search uk transform employability increase proportion reduce injury young people learn disability woman management illness rate provide pulse volunteer bring skill knowledge energy expertise provide resilience training susan scottparker obe employee include advice reduce found chief executive business disability forum stress improve energy level httpbusinessdisabilityforumorguk gsk corporate responsibility report talent development commit leader manager early career development community involvement employer want build capability leader early career development programme choice recruiting manager develop team create include internship industrial placement community involvement valuesbase culture demonstrate apprenticeship graduate scheme programme pulse orange day retain strong leadership global mba programme esprit enable employee develop skill talented people broaden perspective engage employee value account recruit graduate world develop valuable contribution outside gsk pulse significant proportion senior leader make progress provide month assignment skill invest annual performance assessment line global target recruiting graduate employee work fulltime manager assess deliver year new graduate programme employee nongovernmental organisation charity work deliver launch communication human orange day programme give level early career leader year undertake degree resource consumer healthcare unit employee pay day year volunteer assessment direct line significantly increase number senior management choose local community project manager opportunity provide detailed participant emerge market feedback leadership behaviour addition launch pulse nearly launch new esprit mba programme people take recent focus enterprise leadership lead finance consumer healthcare commercial area include malaria access healthcare business programme aim help manager medical research development children health science education widen perspective gain well month complete pulse nearly understand diverse global business apprentice join gsk bring volunteer say energise healthcare challenge number apprentice uk work gsk example senior manager travel gsk site continue assess value pulse participant kenya india visit business hospital commitment reimburse uncap ngo partner organisation survey clinic learn societal tuition fee student recruit find increase retention rate business medical challenge gsk company uk graduate scheme volunteer compare gsk employee help solve population country provide opportunity highpotential colleague feel volunteer employee work closely member return placement bring corporate executive team reinvigorate energy spirit motivation future strategy group fsg examine morale team addition challenge business issue affect gsk pulse ngo partner say volunteer meet date employee take exceed expectation employee complete fsg projectsgsk corporate responsibility report inclusion diversity inclusive introduce inclusive behaviour emerge market employee perspective training usa programme focus employer enable uncover participant unconscious bias aim increase proportion people well understand ensure behaviour consistent gsk emerge market management respond need value explain inclusion position bring broad spectrum originally work gsk diversity increasingly critical background experience people hr manager leave rejoin patient healthcare success gsk employ emerge market asia pacific role hr director support worker market woman japan region represent total gsk pakistan iran afghanistan workforce senior manager help attract give chance experience lead report corporate executive team percentage woman higherlevel function time year later retain motivate region different management position continue grow offer opportunity work nationality represent workforce reflect reflect ambition support employer brand project ceo corporate executive team board gender equity senior level future strategy group base gsk community region show marked progress leadership development programme headquarters london operate asia pacific general carefully manage ensure singapore lead asia pacific talent work manager level woman talented people part world development project appoint opportunity participate vp hr middle east africa nonexecutive director woman employee different nationality task set area represent board exceed participate lead business hub istanbul goal female programme design develop future board representation member summary career gsk general manager corporate executive team woman fulfil day stretch emerge market line leadership represent team interact colleague world initiative deliver language help nurture grow country global mba programme gsk great place work woman management position esprit include participant employee empower value different country reflect way work svp vp director manager total fariha vice president hr middle east africagsk corporate responsibility report inclusion diversity continue ethnic minority disability case study ethnic minority account uk want people disability able employee measure diversity access range recruitment project search uk number employee career opportunity longstanding define nonwhite commitment number disability gsk private employee nonwhite compare organisation business disability sector organisation uk forum uk serme spain global project search initiative help young people learn proportion ethnic minority employee gsk launch project search case disability transition usa increase study right uk education world work usa ethnic minority define black commitment focus disability global african american people hispanic level quote intake student age latino people asian people pacific islander business disability forum found chief join employee corporate american indian people alaskan native executive susan scottparker headquarter september year continue monitor benchmark work experience area usa gsk member industry standard define restaurant security post room north american industry classification gettinghiredcom national talent search continue year study organisation people disability system pharmaceutical medicine project help think differently enhance opportunity hire manufacture example potential young people talented people disability level engage external group represent learning disability provide organisation minority event like national work experience alongside fulltime black mba national society study dramatically increase chance hispanic mbas conference southeast participant find employment asian association conference council experience project participant advancement muslim professional organisation suggest raise conference equal summit employment rate ethnic minority uk usa employees uk usa number project search student gskgsk corporate responsibility report engage employee strive engage employee inform capability area utilise gsk case study broadcast ceo corporate change framework enable manager employee executive team article intranet well support employee change value progress equip senior leader information getting involve manage change make need brief team important game company news provide local context early announce expansion company employee survey major change programme survey employee show listening view phase announce second sense pride working gsk employee share view quarter programme focus increase follow london gsk progress employee advance technology reduce cost olympic paralympic games gsk survey participation rate improve efficiency reallocate resource official laboratory service provider game scientific expertise conscious effect conduct survey survey result facility support integrity restructuring employee aim communicate employee game health achieve organisational financial goal business unit function compete athlete eliminate position redeploy address area improvement run global competition ask employee possible remain employee nominate colleague favourable percentage committed consulting change demonstrate olympic value area gsk value employee number consultation forum friendship integrity equality say understand constitute discussion european works council excellence receive ethical business practice conduct similar body country nomination market job say clear national practice job lose winner receive ticket game accountable business change offer compensation role survey find support outplacement line participant get involve employee feel gsk take appropriate local requirement employment gold challenge fitness event raise action socially responsible compare legislation offer employee support charity event include global norm resilience training employee km challenge employee assistance programme cover km km km gsk undertake significant business range sport gsk team change recent year include new country travel combined distance acquisition joint venture outsource km site closure staff reduction markets favourable percentage area change management low survey slightly well global norm major organisation continue strive improvement especially focus develop leadershipgsk corporate responsibility report health safety wellbeing aim create work communicate effectively healthy highperforming employee perspective employee health safety simplify resilient workforce environment inspire online health safety information support people consistent energy performance personal grow perform safe business streamline health resilience ep training programme provide partnership prevention safety policy standard reduce employee support reduce stress great initiative think go healthy resilient way bureaucracy easy work home improve energy mind shift business focus key priority level productivity additional world treatment employee take prevention great idea wife want health promotion resilience programme study know disease prevention ep graduate sale force show advocate programme increase productivity gsk multinational call month achieve comparison gsk employee employer commit provide comprehensive consumer healthcare nigeria control group preventative healthcare service employee dependant worldwide programme manage attendance year commitment ensure employee receive proper medical read online mission help people care support help return work feel well live long safely quickly usa attendance publish detail online key call partnership prevention new management programme save approximately issue include million reduce time away programme provide access affordable hazardous chemical management work disability return healthcare prevention service gsk reach employee work soon industry employee country healthcare average measure employer measure provision expensive inadequate productivity absence quality programme expand access service include immunisation cancer screening smoking cessation programme hiv screen treatment cover health insurance service provide community healthcare network gsk site programme pilot employee gsk employee family assure ecuador ghana nigeria romania result additional allow develop global approach employee take resilience programmesgsk corporate responsibility report health safety wellbee continue zero harm help embed safety culture datum summary injury illness datum focus reporting near miss incident goal zero harm employee enable learn mistake injury illness rate decrease hour work million achieve goal eliminate prevent accident routinely perform audits compare slip trip fall fatality incident risk employee vary ensure reduce manage risk lead cause injury illnesse number injury illnesse accord role include chemical effectively review health safety accounting nearly incident lose time exposure drive accident repetitive commercial business result calendar day lose strain injury extend network leading cause gsk reportable injury number injury illnesse illness lose time incident environmental health safety coordinator losttime injury illness rate gsk globally commercial sale globally hrs work employee die motor vehicle accident continue embe risk reduction c pa ele r n r ys h l ro ss w r oa rt ke e routine call physician programme zero access reportable injury illness rate incident occur india machinery respirator free initiative hrs work argentina result driver safety aim minimise risk injury note programme expand accident reduce exposure data cover employee contract worker directly manufacture site machineryrelate harmful airborne powder deployment ilu lnp ee sr sv pis ee rd f ob ry g nk ce e fm orp tlo hy ee ye es rw ce r se ep mrt bn ea ap dsh et af f tin ej ru tr hy e en nd incident result finger amputation process safety management system slipstripsfall year datum prior year change incident occur china prevent catastrophic event e mrg ao chn io nm eryic l ilo lns et st sim ese hin aju r aie res sa en rd io ulln e es ns oe ga hre ow ro er sk ur lte il nat oed n ein oju r r mie os ra en dd ys belgium following rootcause analysis fire explosion release hazardous motor vehicle la ow sa c afr leo nm aw r dr ak day include weekend investigation machinery safety substance remain target contact sharp object employee work workrelate injury specialist tianjin site china illnesses indicate severity injury illnesse r eportable injury illnesse lose time incident corrective action plan develop result time away work teleconference hold review lesson reportable injury ilness rate learn vaccine facility belgium hour work environment health safety datum reinforce equipment safety report assure bureau verita training implement comprehensive read assurance statement preventative maintenance plan response assure targetgsk corporate responsibility report reward recognition open executive pay pension case study remuneration practice management executive level propose pension benefit change ensure reward remuneration align business uk cap basic salary increase pa thinking locally performance measure design employee uk definedbenefit plan base performance reward longterm performance term increase think locally come pay reinforce value sustainable shareholder value provide benefit create package form nonpensionable salary supplement attractive competitive board level remuneration committee engage consultation local location vietnam example set remuneration policy level national basis include provide loan employee cover corporate executive team responsibility manufacturing trade union output purchase new motorcycle ensure reward appropriate consultation able registration tax insurance competitive industry wide market amendment original proposal year give employee reliable norm annual report detail total propose change effect form transport provide remuneration earn available consider cost management advantage attract executive director change benefit seek retain talent put value continue strike right balance heart reward company employee interest fairness equity continue align employee reward benefit reflect value aim provide consistent fair reward different way appropriate global location tailor benefit develop country market suit local circumstance case study access unit dcma set increase senior employee patient access gsk medicine vaccine structure bonus longterm incentive build sustainable business consistent regardless location leastdevelope country objective reward manager unit base primarily volume profit help ensure medicine reach need behaviour sale marketinggsk corporate responsibility report planet focus reduce carbon footprint green method make antibiotic read section overview carbon water waste managing impact engagement datum summary summary assurance statement gsk corporate responsibility report planet focus amoxicillin widely grow business bring prescribed antibiotic world sustainable gsk manufacture billion tablet innovative medicine people year antibiotic large antibiotic carbon footprint product world commit base sale projection footprint increase reduce environmental traditional process synthesise amoxicillin require energyintensive cool large volume organic solvent create impact waste green chemistry team site singapore develop way enzyme environmental sustainability priority gsk effect cut carbon emission process climate change water scarcity undermine hardwon tonne reduce organic waste tonne improvement global health natural resource rely produce medicine product enzyme couple compound water form amoxicillin scarcer expensive stakeholder expect manage few step cool few organic environmental impact responsibly solvent traditional chemical goal reduce process innovation make important reducing footprint resource efficiently carbon footprint contribution goal reduce work tackle challenge reduce cost business carbon footprint business build competitiveness create trust business antibiotic sell highly competitive market improvement set ambitious goal reduce carbon water waste help differentiate product value chain use raw material impact announce plan invest million singapore dollar supplier footprint lab factory use convert enzymatic amoxicillin disposal product patient consumer meet manufacture quality road site goal involve employee partner singapore read onlinegsk corporate responsibility report overview glance carbon establish inhaler recovery recycling commitment external perspective service uk usa chile collect despite reduce carbon energy use inhaler uk reduce overall carbon footprint total carbon footprint vs exclude raw material carbon neutral value chain company organisation increase drive high inhaler sale reduce water impact public private closely examine value chain vs add social business value operate financial reduce operational waste environmental limit gsk rise vs challenge commit water build sustainable supply line examine environmental footprint nutrition portfolio work local reduce water consumption product service move farmer improve agricultural operation compare forward gsk need improve practice improve yield competitiveness livelihood environmental efficiency product service time acknowledge need adapt manage impact core business service create green chemistry promote protect health performance unit research way replace hazardous chemical process low impact alternative pledge million establish centre excellence green chemistry collaboration university nottingham uk waste cut total waste send waste landfill compare engagement engage supplier david pencheon carbon water director nhs sustainable development unit waste reduction httpwwwsdunhsuk gsk corporate responsibility report carbon longterm goal understand co value chain carbon footprint million tonne annum tpa value chain carbon neutral mean raw material need look estimate impact supply chain raw estimate material source account carbon process associated million tpa footprint product work supplier help reduce impact use resource efficiently product source raw material manufacturing operation co generate operation use product disposal operation generate co emission mainly include energy production energy use account product co relate emission hfaa total carbon footprint look way inhal manufacture plus emission process efficient use energy million tpa absolute emission operation transport transport logistic co generate transport logistic inhaler use generate emission business travel aim minimise transport product logistic sale force co carbon footprint increase business travel customer exclude contribution raw material million tpa reduce carbon energy use increase inhaler meter dose inhaler use co generate meter dose inhaler use sale result rise carbon emission associate use meter inhaler use dose inhaler account value chain co million tpa carbon footprint co product use emission associate use product boiling water horlick patient estimate use product eg boiling water customer account overall footprint horlick million tpa end life assure emission disposal product carbon footprint inhaler big disposal impact start collect inhaler recycle million tpa reduce contribution base assume value chain footprint million tonne cogsk corporate responsibility report carbon continue performance achieve upgrade onsite power generation case study global certification carbon trust facility combine heat power plant standard certifie operate unit company make yearonyear overall site save tonne co cut carbon footprint horlick reduction emission associate equivalent year approximately operation transport time period energy need supply renewable horlick nutritional drink additionally introduce gsk multinational source energy site second large source carbon emission lowcarbon biomass energy generation achieve standard date product range inhaler horlick factory waste wood continue research specific aspect estimate tonne co replace coal expect performance carbon footprint help identify cut emission horlick save tonne co equivalent opportunity reduction end important step meet annually carbon footprint exclude complete carbon footprint climate change goal contribution raw material analyse product currently measure annual basis analyse carbon footprint identify change reduce emission increase compare horlick find milk manufacture use focus reduce carbon footprint energy production account half project potential achieve operation compare emission value chain tackle significant reduction ignore increase sale result rise carbon go source buffalo opportunity small change footprint product transportation use dairy cow enhance establish add big saving disposal meter dose inhaler indian government programme help account approximately value participate carbon disclosure farmer learn modern milk chain carbon footprint increase inhaler project investorle initiative aim technique give access sale result rise greenhouse improve transparency corporate well veterinary care increase milk production cow gas emission inhaler use compare carbon emission report annually reduce overall carbon footprint carbon reduction project policy programme project underway enable performance area detail see reach interim target cut value cdp website chain carbon footprint million collaborate organisation tonne co equivalent national health service sustainable development unit association british pharmaceutical industry develop carbon footprinting guidance pharmaceutical company assure bygsk corporate responsibility report water waste minimise waste water follow suggestion employee waste instead pull fresh water local water use help reduce gsk signatory un ceo water supply stage water recycle reduce total environmental footprint mandate initiative help company save million litre year waste hazardous nonhazardous improve efficiency develop implement disclose sustainable water plant compare make progress water practice target cut waste save money protect nabha india waterstresse demonstrate commitment region staff achieve limited natural resource working government civil society reduction water use reduce waste send landfill stakeholder protect fulfil million litre million litre compare work goal human right water define united measure include make sure water zero waste landfill total nation particular reduce use measure meter manufacturing site send waste water consumption part world pressure hose general cleaning landfill reduction big difference reuse treatment water water plant number measure include develop longerterm water strategy recirculate cool water recovery solvent input ngo build commitment manufacture active pharmaceutical water mandate plan respond annually cdp water ingredient improve waste segregation launch disclosure project investorle initiative plant office support sustainable corporate water use fresh water manufacturing process management late submission product drink project find cdp website vaccine value chain water footprint associate source raw material instance milk net water consumption operation total waste generate product horlick million cubic metre thousand tonne target reduce impact water consumption value chain end think important cubic metre exclude nonroutine start operation ask waste construction demolition change learn valuable lesson share supplier total waste effective idea reduce water use target assure come employee especially water stress area example plant port fairy australia water require stage manufacturing process target targetgsk corporate responsibility report water waste continue waste landfill hazardous waste incinerate tonne packaging survey response supplier year save tonne thousand tonne co equivalent packaging product highly oto u rd te rgti ef ty prioritise action meet visible patient consumer aim mass efficiency use paper packaging material continue recycle pet packaging wood grow harvest tray deliver component site progress improve responsibly survey supplier ware uk evreux france mean mass efficiency measure carton board packaging corrugate packing purchase recycled pet open market waste landfill raw material require target leaflet paper rainforest alliance ribena bottle new active pharmaceutical ingredient develop internal policy recycle pet weighted account scale manufacture prioritise large scale process introduce new chemistry solvent recovery case study big benefit mass efficiency figure represent snapshot performance inhaler recycling programme target product transfer manufacture large scale process recover solvent patient finish gsk inhaler flowerpot remain gas develop solvent recovery process result inhaler usually end landfill waste capture metal component water exclude solvent average mass efficiency complete cycle new recovery recycle material low volume product transfer recycle programme aim reduce inhal recycling scheme active pharmaceutical ingredient use mass efficiency slightly low waste uk expand chile explore option tonne solvent year good improvement pilot programme collect australia japan czech republic recover reuse mass efficiency primary process weo r vh ea sn v e n toh na nle er ss w f ce e ti om da te e h hungary nordic country reuse solvent significantly reduce make complete cycle manufacturing work waste save money disposal available uk supplier presspart group use buy new solvent recycle aluminium can ventolin usa expand similar seretide advair flixotide meter dose continue look opportunity programme city inhaler possible result carbon manufacture instance participate pharmacy receive kit emission produce can gsk introduce recovery diisopropyl ether include special container customer reduce tonne solvent ulverston uk drop inhaler pharmacy supply manufacture antibiotic reduce prepaid envelope inhaler co equivalent year send freeofcharge specialised assure recycler plastic new household product plastic target co savedgsk corporate responsibility report manage impact addition priority green chemistry chlorofluorocarbon cfc refrigerant compliance fine focus area carbon water green chemistry aim replace hazardous working eliminate fine report year waste manage chemical process inventory chlorofluorocarbon cfc internal audit small environmental impact refrigerant deplete ozone layer range important audit operation sure create green chemistry performance unit remove environmental issue green chemistry theory practice remain cfc tonne dispose environmental risk impact identify manage effectively unit publish internal guide large piece chill equipment need audit determine base help employee well chemical choice cfc recover safely destroy business knowledge modelling risk design develop product sell building contain indicator trend previous audit large chiller unit party mean year formalise million finding team responsible auditing low volume cfcs collaboration university environmental health safety eh collectively kg small piece nottingham uk establish centre certify iso environmental equipment site world excellence green chemistry management lead auditor dispose safely time construct carbon neutral sustainable equipment decommission ehs audits site chemistry laboratory centre schedule completion remediation globally different business unit audits include review encourage development clean waste disposal industrial activity environmental management system safe efficient process contaminate soil surface ground water management environmentally pharmaceutical environment gsk take responsibility environmental hazardous material waste water remediation work facility audit theme manufacture site pharmaceutical completely previously disposal site waste result number improvement absorb broken body management company residue find way read ehs audits key supplier go business environment excrete unused supply chain section currently environmental remediation site medicine dispose consumer world gsk policy statement pharmaceutical sole responsibility environment available online continue participate research important spend million issue partner university environmental remediation estimate birmingham cambridge york future remediation work cost uk working industry trade approximately million assure association european federation pharmaceutical industry associationsgsk corporate responsibility report engagement engagement engage employee engage supplier employee supplier need employee understand carbon footprint lie read online helps deliver strategic environmental challenge face value supply chain engage environmental objective contribute team individual supplier reduce environmental publish detail online key achieve impact carbon footprint analysis issue include environmental issue employee involve set product start point climate change complex global network sustainability advocate begin talk supply chain hazardous chemical management partner carbon water waste address employee typically volunteer genetically modify microorganism reduction ask datum environment health safety ehs role enthusiast promote effectively environmental footprint gsk reach sustainability colleague change work practice behaviour work home organise workshop work gsk convention biological diversity identify opportunity carbon saving nanomaterial advocate help establish waste reduction engage key supplier ozone depletion metereddose inhaler programme encourage employee share environmental issue asthma good environmental practice promote pharmaceutical environment community project increase impact climate change health awareness advocatele project result use ozonedeplete substance saving gsk use social network ancillary plant equipment encourage discussion generate idea enable employee new connection ceo run annual award recognise contribution innovation team company environment health safety sustainability year entry sustainability award section assure bygsk corporate responsibility report datum summary environment health safety datum performance datum summary report assure bureau verita target read assurance statement change change note note note response carbon thousand tonne coequivalent annum detailed breakdown metric carbon footprint note note note datum download climate change impact available online raw material note note operation operational energy source note operational energy transport product transport note note employee air travel sale force vehicle inhal use patient water million cubic metre water use operation waste thousand tonne total operational waste generate total operational waste landfill value restate previous report estimate datum include actual datum available reassess carbon footprint value chain annual performance available investigate use phase product partnership university manchester uk estimate use product include inhaler add approximately million tonne coe value chain footprint revise emission factor refrigerate cargo ocean transportation publish nd international marine organisation imo ghg study restate data source include co equivalent impact inhaler production loss leak chiller productionrelate release waste treatment relate release baseline assure bygsk corporate responsibility report summary assurance statement basis report site select review scope methodology include gsk response assurance external assurance gsk business sitespecific audits assessment ehs datum associate datum conduct site datum verify management process involve detailed pleased bureau vertita energy co emission datum collect source special focus review integrity select dataset finding gsk progress manage pharmaceutical site contributor datum aggregation check process reduce ehs impact commit consumer healthcare manufacturing site environmental emission previous year corporate level sample datum continue improvement ultimate vaccine site pharmaceutical site previously visit source gsk site site goal provide accurate ehs data consumer healthcare rd site uk prior year site difficulty choose represent manufacture site public website headquarters building office submit datum timely manner great emission range different continue work improve distribution centre water nonhazardous gsk operation ie gm vaccine data accuracy emphasis bureau verita summary waste datum collect rd geographical spread interview incorporate recommendation provide independent assurance statement manufacture vaccine operation undertake ehs directors bureau veritas rd major office location base bureau veritas uk ltd engage understand gsk sustainability strategy read gsk response assurance materiality assessment collect gsk provide independent assurance objective target implementation plan hazardous waste wastewater data environment health safety ehs datum progress office site manufacture consumer relate information people bureau verita opinion gsk healthcare nutritional product planet section corporate corporate responsibility report demonstrate volatile organic compound voc responsibility report report page understand ehs material issue report site manufacture undergone assurance indicate gsk generally good progress pharmaceutical contain rd pilot plant bureau verita logo comment manage reduce ehs impact use greenhouse gas protocol assure bureau verita assurance report provide fair summary ehsrelated calculation co emission statement find include activity performance metric datum energy use propellant refrigerant detail scope work methodology free omission significant error use co country factor electricity finding recommendation publish international energy improvement assurance statement include agency recommendation improvement include refinement datum collection process year bureau veritas uk ltd engage gsk provide independent assurance environment health safety eh datum relate information people planet section corporate responsibility report london february gsk corporate responsibility report governance engagement good governance governance boardlevel audit risk committee audit assurance transparent reporting focus key business risk area assess aspect responsibility corporate executive team cet gsk include nonfinancial reputational performance internal commitment head ceo andrew witty accountable risk support risk oversight external assurance process audit open responsible management business compliance council rocc ensure assurance department responsibility oversee relevant policy effective internal control implement independently assess adequacy business activity program gsk significant risk rocc chair effectiveness management engage stakeholder directly cet member participate board corporate compliance officer significant risk area report outcome understand prioritise level corporate responsibility committee include member cet audit risk committee line crc crc provide highlevel guidance member include general counsel agree assurance plan include issue approach review policy company secretary head audit assess sample basis process important progress crc assurance additional member add control place comply law member sir christopher gent chair appropriate regulation company standard gsk dr stephanie burn dr daniel podolsky manage specific issue governance audit team recommend improvement lynn elsenhans join october body sustainability steering team issue identify gsk manager crc meet time year consist senior leader develop action plan address cause frequently necessary report senior business bring perspective gsk noncompliance gap internal control manager member cet enable different business environmental debate audit assurance track plan member review ensure progress shape environmental strategy make completion report result senior responsible management business sure intergrated management audit risk committee committee report finding read assurance internal audit board year summary risk management governance section cr committee report contain annual report annual report annual report detailsgsk corporate responsibility report governance engagement continue stakeholder engagement meeting investor discuss aspect reporting gsk responsible business strategy engagement dialogue enable report performance annually understand need key stakeholder employee survey receive report commitment open touch view feedback response respondent transparent business activity allow identify important issue participation rate give responsible business cover current emerge shape valuable insight staff view annual report response issue ensure strength weakness gsk reporting standard good interest wide society global reporting index show shareholder help build broad range engagement ngo element guideline cover trust gsk international organisation government report member un global engagement take place policymaker well understand compact gsk publish index normal course business daytoday issue increase access reporting line interaction customer employee healthcare sustainable way global compact expectation supplier partner carry act cochair uks industry formal structured engagement government forum access medicine datum coverage include meeting consultation participate partner forum datum report relate worldwide survey participation conference uk government global health strategy operation calendar year debate provide training help manager attend executive board meeting state data market communicate local world health assembly participate environment health safety stakeholder approach responsible board member gavi alliance section independently verify business transparency roll malaria partnership engage bureau verita brand name appear intergovernmental meeting italic report example engage stakeholder pandemic influenza preparedness trademark own andor license include throught report addition gsk associate company undertake consultation non governmental organisation global public health group socially responsible investor sustainability think tank gsk exist future responsible business commitment include roundtable meeting interview survey facilitated business social responsibility help shape promise goal wwwgskcom feedback count find downloadable pdfs welcome feedback responsible business performance report annual report let know like receive annual summary regular update progress form f csrcontactgskcom corporate responsibility report head office register office search glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel register number photocredit cover health divid marcus perkin behaiour divid getty image people divid tom whipps planet divid getty image